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ABSTRACT
Carotenoids are colourful compounds, present in fruits and vegetables,  synthesised by plants and
micro-organisms. About 10% of these are important dietary precursors of vitamin A. Carotenoids
act as antioxidants and possibly decrease in-vivo lipid oxidation. Lipid oxidation is known to be a
risk factor for atherosclerosis. Carotenoids are thought to be responsible for the beneficial
properties of fruits and vegetables in preventing human diseases, including cardiovascular diseases
and cancer. In recent years, the antioxidant properties of carotenoids have become a major focus of
research. The aim of this thesis was to develop a high performance liquid chromatographic (HPLC)
method for determination of carotenoids from blood plasma and to study the role of carotenoids in
lipid oxidation and cancer.
We developed and validated an HPLC method for analysis of carotenoids (lutein,  zeaxanthin,
-cryptoxanthin,  lycopene,  -carotene  and  -carotene)  that  appears  to  be  simple,  quick  and
repeatable. Serum concentrations of carotenoids, except for lycopene, tended to increase in men and
women as  they  became older,  indicating  an  increase  in  the  consumption  of  fruits  and vegetables
from the late 1980s to the beginning of the 2000s. The decrease in lycopene concentrations found in
both sexes during follow-up years suggests that elderly people may not consume as many tomatoes
and tomato products as do young people.
We investigated the effects of astaxanthin supplementation (8 mg/d) on lipid oxidation in
healthy  men  and  its  safety  as  a  supplement.  When  supplemented  as  capsules,  astaxanthin  was
efficiently absorbed from the intestine into the blood circulation and was well tolerated. An almost
significant decrease was found in 15-hydroxy fatty acid concentration after astaxanthin
supplementation for three months. The serum low density lipoprotein (LDL) content of conjugated
dienes is an in vivo lipid oxidation marker. We observed that in addition to gender, lycopene,
lutein and -carotene were the most powerful determinants for serum LDL conjugated dienes in
Eastern  Finnish  men and women.  A diet  rich  in  vegetables  and carotenoids  can  decrease  in  vivo
LDL oxidation and thus slow down atherogenesis. We also studied the association between the
serum concentration of lycopene and the risk of cancer. Men with serum lycopene concentrations
higher than 0.19 μmol/l had a 45% lower risk for total cancer than did men with lycopene under
0.08 mol/l. However, lycopene was not associated with prostate cancer in this population.
In conclusion, serum/plasma carotenoids may decrease lipid oxidation in vivo. In addition,
high serum concentrations of lycopene may decrease the risk of cancer in middle-aged Finnish
men.
National Library of Medicine Classification: QV 325, QU 110, QU 85, QZ 200
Medical Subject Headings (MeSH): Antioxidants; Carotenoids/blood; Cholesterol; chromatography, High
Pressure Liquid; Lipoproteins, LDL; Lipids/blood; Lipid Peroxidation; Neoplasms
VI
VII
Karppi, Jouni. Karotenoidien määrittäminen ja merkitys rasvojen hapettumisessa ja syöpätaudeissa. Itä-
Suomen yliopiston julkaisuja. Terveystieteiden tiedekunnan väitöskirjat 43. 2011. 72 s.
ISBN: 978-952-61-0362-4
ISSN: 1798-5706
ISSNL: 1798-5706
ISBN: 978-952-61-0363-1 (PDF)
ISSN: 1798-5714 (PDF)
TIIVISTELMÄ
Karotenoidit ovat kasvien ja pieneliöiden (levät, bakteerit, sienet) tuottamia värillisiä yhdisteitä,
jotka antavat värin niitä sisältäville hedelmille ja vihanneksille. Noin 10% kaikista karotenoideista
on A-vitamiinin esiasteita. Karotenoidit toimivat elimistössä antioksidantteina ja vähentävät
mahdollisesti rasvojen liiallista hapettumista, joka on ateroskleroosin riskitekijä.
Karotenoidipitoisten kasvisten runsaan saannin on todettu mm. vähentävän riskiä sairastua sydän-
ja verisonitauteihin, syöpätauteihin ja muihin kroonisiin sairauksiin. Tämän väitöskirjatyön
tarkoituksena oli kehittää nestekromatografinen menetelmä karotetoidien määrittämiseksi
veriplasmasta sekä tutkia karotenoidien merkitystä elimistön rasvojen hapettumisessa ja
syöpätaudeissa.
Kehitimme ja validoimme karotenoideille (luteiini, zeaksantiini, -kryptoksantiini, lykopeeni,
- ja -karoteeni) nestekromatografiamenetelmän, joka osoittautui helpoksi, nopeaksi ja
toistettavaksi. Itäsuomalaisessa väestössä karotenoidien pitoisuudet nousivat naisilla ja miehillä
heidän ikääntyessään, joka osoittaa hedelmien ja vihannesten käytön lisääntyneen 1980-luvulta
2000-luvulle. Sitä vastoin seurannan perusteella näyttäisi, että iän myötä itäsuomalaiset syövät
vähemmän tomaatteja ja tomaattipohjaisia elintarvikkeita kuin nuoremmat, koska seerumin
lykopeenipitoisuus väheni tutkittavien ikääntyessä.
Selvitimme astaksantiinilisän (8 mg/vrk) vaikutusta ihmisen elimistön rasvojen hapettumiseen,
astaksantiinin imeytymiseen, plasmapitoisuuksiin ja arvioimme astaksantiinin turvallisuutta
ravintolisänä. Astaksantiini imeytyi hyvin kapseleista verenkiertoon ja oli hyvin siedetty. 15-
hydroksirasvahapon pitoisuudessa havaittiin lähes merkitsevä väheneminen kolmen kuukauden
astaksantiinilisän käytön jälkeen. Seerumin LDL:n konjugoituneiden dieenien määrää mittaamalla
saadaan tietoa LDL:n in vivo hapettumisesta. Havaitsimme, että sukupuolen lisäksi plasman
lykopeeni, luteiini ja -karoteeni ovat tärkeimmät seerumin LDL:n konjugoituneiden dieenien
määrään vaikuttavat tekijät itäsuomalaisten miesten ja naisten aineistossa. Kasvisravinnosta
saatavat karotenoidit saattavat vähentää hapetusreaktioiden aiheuttamia muutoksia LDL:ssä ja
hidastaa aterogeneesiä. Tutkimme myös seerumin lykopeenin ja syöpäriskin välistä yhteyttä.
Havaitsimme kokonaissyöpäriskin olevan 45% pienempi miehillä, joiden seerumin
lykopeenipitoisuus oli yli 0.19 μmol/l kuin miehillä, joilla se oli alle 0.08 umol/l. Pelkästään
eturauhassyöpään ei lykopeenilla ollut tässä aineistossa yhteyttä.
Työssä havaittiin, että korkeat karotenoidipitoisuudet seerumissa/plasmassa saattavat vähentää
elimistön rasvojen hapettumista. Lisäksi korkea lykopeenipitoisuus seerumissa voi vähentää
kokonaissyöpäriskiä keski-ikäisillä itäsuomalaisilla miehillä.
Yleinen suomalainen asiasanasto (YSA): antioksidantit; karotenoidit; lykopeeni; lipiditveri; lipidit
hapettuminen; nestekromatografia; LDL-kolesteroli; syöpätaudit
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1 Introduction
Reactive oxygen species (ROS) (i.e., free radicals) form through normal aerobic
metabolism. Life-style (smoking, alcohol) and diet produce free radicals that can
damage biological macromolecules, such as proteins, DNA, cholesterol and
polyunsaturated fatty acids of LDL (Tapiero et al. 2004). This oxidative stress has
been suggested as leading to an increased risk of chronic degenerative diseases,
such as cardiovascular diseases (Witztum 1994) and cancers (Ames et al. 1995).
Dietary antioxidants including carotenoids from fruits and vegetables have been
shown to be effective compounds for preventing the risk of chronic diseases by
reducing oxidative stress (Jackson et al. 2008).
Carotenoids are widespread in nature and are prevalently found in plants,
animals, and microorganisms. Carotenoid-like pigments are responsible for the
yellow, orange, and red colors of various fruits, vegetables, flowers, birds, fish, and
crustaceans (Jackson et al. 2008). They are also used as natural colouring agents in
the food industry. Lycopene, -carotene, -carotene, lutein, zeaxanthin and -
cryptoxanthin are major carotenoids found in Western diet (Krinsky & Johnson
2005).
Carotenoids have various biological effects on human health. The antioxidant
activity of carotenoids has been suggested as having a significant beneficial effect
on health (Rao & Rao 2007). Recent studies have shown that carotenoids may
contribute to other mechanisms, including gap junction communication, cell
growth regulation, modulating gene expression, immune response and as
modulators of drug metabolizing enzymes (Paiva & Russell 1999; Astrog 1997;
Bertram 1999; Jewell & O'Brien 1999).
 Many previous epidemiological and intervention studies support a role for
carotenoids in the prevention of lipid oxidation in vivo (Kioskias & Gordon 2003;
Iwamoto et al. 2000; Visioli et al. 2003; Chopra et al. 2000), though this effect has
not been observed in all studies (Hininger et al. 2001; Carroll et al. 2000; Freese et
al. 2002). A number of epidemiological studies have shown an inverse association
between carotenoid intake/plasma concentrations and cancers (Zhang et al. 2007;
Lee et al. 2009a; Jenab et al. 2006; Jiang et al. 2005), but the results have been
inconsistent (Peters et al. 2007; Albanes et al. 1995; Männisto et al. 2007; Gallicchio
et al. 2008).
The aim of this work was to develop a rapid, simple method for analyzing
carotenoids from blood plasma, and to study the role of carotenoids in lipid
oxidation in  elderly  men and women and the risk of  cancer  in  middle-aged men
living in Eastern Finland.
22 Review of the literature
2.1 CAROTENOIDS
Carotenoids are a group of colourful compounds that are synthesised by plants
and micro-organisms, but not by animals (Rao & Rao 2007). In 1831, Wachenroder
crystallized a hydrocarbon pigment from carrot roots that he called “carotene”
(Wachenroder 1831). Soon thereafter, Berzelius extracted the more polar yellow
pigments from autumn leaves and called them “xanthophylls” (Berzelius 1837).
Tswett separated numerous pigments of this class chromatographically and began
to  call  the  whole  group  “carotenoids”  (Tswett  1911).  Today,  more  than  750
carotenoids have been isolated from natural sources, of which about 50 are present
in the human diet and about 20 have been identified in human blood and tissues
(Rao & Rao 2007). The most common carotenoids in the human body are lutein,
zeaxanthin, -cryptoxanthin, lycopene, -carotene and -carotene (close to 90% of
all carotenoids) (Rao & Rao 2007). Astaxanthin is synthesised by plants and algae
(e.g. haematococcus pluvialis) and is distributed mainly in aquatic animals including
salmon, trout, red seabream, shrimp, lobster, and fish eggs (Guerin et al. 2003).
2.1.1 Chemistry
The structure of carotenoids is based on a C40 isoprenoid skeleton that may be
acyclic or have one or both ends modified into rings. All C40 carotenoids are
derived from the acyclic tetraterpene, lycopene. Lycopene is biosynthesized from a
total of eight C5 isoprene units. Initially, four C5 units combine to produce the C20
intermediate geranylgeranyl diphosphate, and two C20 precursors combine in a
head-to-head fashion to form the C40 intermediate phytoene, the more saturated
precursor of lycopene. Other carotenoids are synthesized from lycopene by
modifications, such as cyclizations, oxidative functionalizations, rearrangements,
and oxidative degradations (Jackson et al. 2008). The molecular structures of
common carotenoids and astaxanthin are presented in Figure 1.
Carotenoids are divided into hydrocarbon carotenoids and xanthophylls
(Jackson  et  al.  2008).  Lycopene,  -carotene  and  -carotene  belong  to  the  class  of
hydrocarbon carotenoids. They contain 11 conjugated double bonds and two non-
conjugated double bonds. Xanthophylls such as astaxanthin, lutein, zeaxanthin, -
cryptoxanthin also have 11 conjugated double bonds and at least one hydroxyl
group, due to which they are more polar than hydrocarbon carotenoids.
Approximately 50 of the known carotenoids are precursors of vitamin A (Krinsky
& Johnson 2005). Owing to its two unsubstituted -ionone rings at the ends of the
isoprenoid  chain,  -carotene  is  the  carotenoid  with  the  highest  pro-vitamin  A
activity,  while  other  carotenoids  such  as  -carotene  and  -cryptoxanthin  have
lower activities (Yonekura & Nagao 2007).
31.
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Figure 1. Molecular structures of common carotenoids and xanthophylls. Carotenoids: 1. Lycopene, 2. -Carotene, 3. -
Carotene. Xanthophylls: 4. -Cryptoxanthin, 5. Lutein, 6. Zeaxanthin, 7. Astaxanthin.
  Carotenoids have highly conjugated double-bond chains and therefore they
absorb  light  at  the  wavelength  range  of  400  to  500  nm.  Absorption  spectra  of
carotenoids contain three peaks, or two peaks and a shoulder (De Leenher et al.
2000).
  Natural carotenoids occur mainly in their thermodynamically more stable all-
trans configuration, while the cis isomers are only present in minor amounts and
have been demonstrated to be formed as a consequence of food processing, such as
heating and illumination (Aman et al. 2005). Cis-trans isomerization may occur at
any double bond of the carotenoid polyene chain, leading to a large number of
mono-and  poly-cis  isomers  (Britton  1995).  It  has  been  observed  that  in  human
serum and tissues, more than 50% of the lycopene and ~5% of the -carotene exists
4in the cis conformation (Stahl et al. 1992). They are unstable in the presence of light,
oxygen and heat. Most of carotenoids are singlet oxygen quenchers (Di Mascio et
al. 1990), of which lycopene is the most efficient because it contains the highest
number of double bonds (Di Mascio et al. 1989).
  Astaxanthin contains hydroxyl and keto endings on each ionone ring that
explain some unique properties; such a translocation of the terminal rings of
astaxanthin should be advantageous for scavenging the lipid peroxyl radicals in
the membrane and the reactive oxygen species at the membrane surface. Indeed, it
has been suggested that astaxanthin may scavenge radicals inside the membrane
both  by  the  conjugated  polyene  chain  and  the  terminal  ring  moiety  (Goto  et  al.
2001) (Figure 2).
Figure 2. Schematic representation of the possible locations of astaxanthin molecules having inter- and
intramolecular hydrogen bonds in the phospholipid membrane.
2.1.2 Bioavailability and metabolism
The release of carotenoids from a food matrix is an important initial step in its
absorption. Carotenoids are absorbed better from heat processed plant foods than
from unprocessed sources, with the the absorption being increased by dietary fat
(Yonekura & Nagao 2007; Bohm & Bitsch 1999; Stahl & Sies 1992). For instance, the
amount of -carotene absorbed from cooked carrots has been found to be 65% and
from raw carrots 41% (Livny et al. 2003). Absorption of carotenoids in the
gastrointestinal tract is <50%, with the rest being excreted with the feces (Erdman
et  al.  1993b).  After  dissociation  of  protein-carotenoid  complexes,  carotenoids  are
emulsified into small lipid droplets in the stomach and transferred into mixed
micelles (composed of bile salts, free fatty acids, monoglycerides and
phospholipids) in the intestinal lumen. Once packed into mixed micelles,
carotenoids can be absorbed by the small intestinal epithelium (enterocytes) via
5simple diffusion and receptor-mediated transport (Yonekura & Nagao 2007, Parker
1996), where they are packed into triglyceride-rich chylomicrons and transported
into blood circulation via the lymphatic system. Carotenoids achieve maximum
levels in the plasma within a few hours (e.g., ~5 h for -carotene) (Parker et al.
1999). Elimination half-life (t(1/2) takes several days. For instance, 5-7 days for -
carotene and 2-3 days for lycopene, respectively (Schwedhelm et al. 2003).
  Provitamin A carotenoids (-carotene, -carotene and -cryptoxanthin) are
partly converted to vitamin A, primarily retinyl esters, in the intestinal mucosa.
Carotenoids can be enzymatically cleaved into vitamin A, if the carotenoid
contains an unsubstituted -ionone ring with a polyene side-chain of at least 11
carbon atoms. Cleavage is catalyzed by an O2-dependent dioxygenase. Essentially,
two retinal molecules produced from carotenoid cleavage are reduced to retinol
(Tapiero et al. 2004) (Figure 3). However, in reality, conversion of -carotene and
other provitamin A carotenoids into vitamin A is ineffective (Shils et al. 2006).
Vitamin A is an essential micronutrient for cell growth, embryonic development,
vision, and immune system function (Jackson et al. 2008).
O 2
O
O
C entral clea vag e generates tw o
m o lecu les of retina l
 -C arotene
N A D H
O H R etin ol (v itam in A )
O H
D esatu ration extend ing conju gation
D eh yd roretinol (vitam in A 2)
Figure 3. Dietary -carotene can serve as a precursor for vitamin A (retinol) in humans/mammals. Cleavage is catalyzed
by an O2-dependent dioxygenase, probably via intermediate peroxide. Vitamin A2 (dehydroretinol) is an analog of retinol
containing a cyclohexadiene ring system. Retinol and its derivatives are found only in animal products. NADH =
Nicotinamide adenine dehydrogenase.
The chylomicrons are rapidly degraded by lipoprotein lipase in the blood stream.
Chylomicron remnants containing carotenoids are rapidly cleared from the plasma
6by the liver (Parker 1996, Yeum & Russell 2002). Carotenoids excrete from the liver
by binding to very low density lipoprotein (VLDL) (Parker 1996).
  Up to 75% of the hydrocarbon carotenoids (-carotene, -carotene and
lycopene) are bound to LDL, while (53%) the polar dihydroxy carotenoids (e.g.,
lutein and zeaxanthin) are found predominantly in high density lipoprotein (HDL)
and lower proportions in LDL and VLDL (Yeum & Russell 2002; Erdman et al.
1993a). Lipophilic carotenoids are mainly located in the core of the lipoprotein,
which may not allow their transfer between lipoproteins at an appreciable rate,
whereas the more polar carotenoids, which are mainly present on the surface of
lipoproteins, are likely to undergo rapid surface transfer, resulting in a more equal
equilibration between LDL and HDL (Parker 1996) (Figure 4).
Figure 4. Absorption, metabolism and transport of carotenoids. Abbreviations: CAR, carotenoids; apo-CAR, apo-
carotenoids; RAL, retinal; VLDL, very low density lipoprotein; LDL, low density lipoprotein; HDL, high density
lipoprotein}.
  Carotenoids are distributed in various tissues, of which adipose tissue is the
most important. Lutein and zeaxanthin are the only carotenoids found in human
blood  that  are  also  found  in  the  macula  of  the  eye  (Handelman  et  al.  1988).  The
testes,  adrenal  glands,  prostate,  breast  and  liver  contain  the  highest  amounts  of
lycopene (Rao et al. 2006). -Cryptoxanthin occurs mainly in liver (Kohlmeier &
Hastings 1995). -carotene and -carotene have been found in the thyroid, kidney,
spleen, liver, heart, pancreas, adipose tissue, ovary, adrenal gland and mucosal
cells (Stahl et al. 1992). In tissues, carotenoids are thought to be metabolized into
small molecules by enzymatic cleavage and/or chemical oxidation with active
oxygen species at conjugated double bonds. The hydroxyl group of xanthophylls
can be oxidatively metabolized into a carbonyl group (Nagao 2009). For example,
the second pathway of -carotene metabolism is the eccentric cleavage, which
occurs at double bonds other than the central 15,15’-double bond of the polyene
chain of -carotene to produce -apo-carotenals with different chain lengths. The
two major sites of -carotene conversion in humans are the intestine and liver.
72.1.3 Dietary sources and intake
In developed countries, 70–90% of dietary carotenoids come from the intake of
fruits and vegetables (Granado et al. 2007). Estimated intakes of carotenoids vary
widely between individuals, regions and nations. Studies also report variations
between seasons (O'Neill et al. 2001; Elia & Stratton 2005). The majority of
carotenoids  are  derived  from  a  few  fruits  and  vegetables  (Granado  et  al.  1996).
Lycopene is found mainly in tomatoes and tomato products, while the principal
sources of -carotene and -carotene are carrots. Lutein and zeaxanthin exist for
example in kale, spinach and maize. The main sources of -cryptoxanthin are citrus
fruits (e.g. oranges) (Osganian et al. 2003). The sources and contents of major
carotenoids in selected foods are presented in Table 1.
Table 1. Sources of major carotenoids in selected foods.
Carotenoid                                 Source                                    (Content μg/100 g wet wt)
 Lycopene Tomato and tomato products        800-94000
                                      Red watermelon                           3500-13500
                                      Pink grapefruit                              750-3400
                                      Papaya                                         7600
                                      Guava                                          770-1800
                                      Rose hip, canned                          780
-Carotene Carrots                                         4400-9800
                                     Apricots                                        590-3000
                                     Mangoes                                       110-1200
                                     Red pepper                                   1400-2400
                                     Kale                                              1000-7400
                                     Spinach                                        3100-4800
                                     Broccoli                                        290-1800
-Carotene                                  Carrots                                         2100-5000
                                     Banana                                         60-160
                                                   Pumpkin                                       1900
                                     Peppers                                        10-300
                                     Avocado                                       17-30
                                     Apricots                                        3-40
 Lutein and zeaxanthin Kale                                             4800-11500
                                     Spinach                                        5900-7900
                                     Broccoli                                        710-3300
                                     Peas                                             1900
                                     Cress                                            5600-7500
                                     Parsley                                         6400-10700
                                     Lettuce                                         1000-4800
                                     Maize                                            50-800
                                     Egg yolk                                       400-1600
-Cryptoxanthin Yellow watermelon                       59-100
                                     Oranges                                        16-1300
                                     Papaya                                         1000
                                     Mango                                          20-320
                                     Red pepper                                   280-450
                                     Pineapple                                      70-120
                                                  Pumpkin                                        60
Data was taken from O'Neill et al. 2001; Osganian et al. 2003; Maiani et al. 2009 and Granado-Lorencio et
al. 2007
8  There are no recommendations for intake of carotenoids, since carotenoids are
not indicated to be essential nutrients for human, unlike vitamin A. Recommended
dietary  allowances  (RDA)  exist  for  vitamin  A  (Tabacchi  et  al.  2009).  Vitamin  A
deficiency is known to cause acne, dry hair, fatigue, growth impairment, insomnia,
hyperkeratosis (thickening and roughness of skin), immune impairment, night
blindness, and weight loss (Underwood 2004). The amount of carotenoids in the
diet is difficult to estimate, partly because the methods used for establishing food
composition tables are not specific or sensitive enough (Rissanen 2003).
  There are major differences in the daily intake of carotenoids between
populations. The daily intake of lycopene from tomatoes and other sources has
been  reported  to  be  0.8  mg  for  men  in  Finland  (Ylönen  et  al.  2003),  whereas  the
intake of lycopene has been found to be 2.1 mg in Spain (Garcia-Closas et al. 2004),
1.2  mg  in  Netherlands  (Männistö  et  al.  2007),  6.6  mg  in  the  USA  (Slattery  et  al.
2000)  and as  high as  7.4  mg in Italy  (Lucarini  et  al.  2006).  The daily  intake of  -
carotene and -carotene has been measured to be 0.15 and 2.6 mg in Italy (Lucarini
et al.  2006), 0.3 and 1.1 mg in Spain (Garcia-Closas et al.  2004), 0.7 and 3.0 mg in
Netherlands (Männistö et al. 2007) and 1.2 mg and 6.4 mg in the USA (Bandera et
al. 1997), respectively. Intakes of -cryptoxanthin and lutein + zeaxanthin have
been identified to be 0.2 and 4.0 mg in Italy (Lucarini et al. 2006), 0.3 and 0.5 mg in
Spain (Garcia-Closas et al. 2004), 0.2 and 3.0 mg in the Netherlands (Männistö et al.
2007), respectively. In Finland, the dietary intakes of -carotene, -carotene, -
cryptoxanthin and lutein + zeaxanthin were reported to be 0.08–0.5, 1.6–3.5, 0.003–
0.025 and 1.0–1.14 mg/d, respectively (Männistö et al. 2007; Ylönen et al. 2003;
Montonen et al. 2004; Kleemola et al. 2002).
2.1.4 Carotenoid concentrations in blood circulation
Blood concentrations of carotenoids have shown great variability among different
populations (Table 2). In a study covering nine European countries (Al-Delaimy et
al. 2004), the plasma concentrations of lutein and zeaxanthin were the highest in
Italy and Greece; -cryptoxanthin was highest in Spanish regions; lycopene tended
to be highest in Italy, Spain and Greece and lowest in Sweden. Concentrations of -
carotene or -carotene did not differ between North and South (Al-Delaimy et al.
2004). Women had generally higher individual carotenoid concentrations in all
regions than men. Variation of carotenoid concentrations between regions may be
a consequence of different dietary intake of fruits and vegetables and influence of
season. It is likely that seasonal fruit and vegetables that are main source of certain
carotenoids (tomatoes for lycopene and citrus fruits for -cryptoxanthin) will have
a significant effect on blood levels (lower in the Northern Europe), although
influence of season has decreased in industrialised countries (Al-Delaimy et al.
2004). Serum carotenoids have also been assessed in five European countries by
Olmedilla et al. (Olmedilla et al. 2001), who similarly have reported wide
variability between Northern and Southern Europe. Spain had the highest -
cryptoxanthin concentrations, while lutein and zeaxanthin were higher in Southern
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Europe (France and Spain) than in the North (Northern Ireland and the Republic of
Ireland). No clear north–south trend was found for -carotene or -carotene
(Olmedilla et al. 2001).
 Reference ranges for serum/plasma carotenoids have been determined only for
lycopene and -carotene in a few Finnish laboratories. Serum concentrations of
carotenoids from a study of five European countries (Spain, France, the
Netherlands, Northern Ireland and the Republic of Ireland) may be considered as
'reference values' in the serum of healthy, non-smoking middle-aged subjects
(Olmedilla et al. 2001). The reference values determined in various populations are
described in Table 3.
2.1.5 Bioactivity
2.1.5.1 Antioxidant activity
Carotenoids have antioxidant activity, which may protect against chronic diseases
by decreasing the oxidative damage of cell lipids, lipoproteins, proteins and DNA
(Poulsen et al. 2000; Stanner et al. 2004). Astaxanthin has been reported to be a 10-
fold stronger antioxidant than -carotene and 100-fold stronger than -tocopherol,
respectively (Naguib 2000). Oxidative stress has been known to be involved in the
initiation and progression of several chronic diseases. Carotenoids principally
scavenge two types of ROS: singlet molecular oxygen (1O2) and peroxyl radicals.
They deactivate effectively the electronically excited sensitizer molecules, which
are involved in the generation of radicals and singlet oxygen (Young & Lowe
2001). Dietary carotenoids protect human lymphocytes from damage by singlet
oxygen 1O2, and may lower the risk for several degenerative diseases, including
cancers, cardiovascular or ophtalmological diseases (Zhao et al. 2006; Lornejad-
Schafer et al. 2007). The efficacy of carotenoids for physical quenching depends on
a number of conjugated double bonds present in the molecule. -Carotene,
zeaxanthin, -cryptoxanthin, and -carotene belong to the group of highly active
quenchers of 1O2 (Cantrell et al. 2003). Lycopene is a potent antioxidant and the
most efficient quencher of 1O2 (Di  Mascio  et  al.  1989).  Scavenging  of  peroxyl
radicals generated in the process of lipid peroxidation interrupts the reaction
sequence, finally leading to damage in lipophilic compartments. Lycopene was
reported to be more effective than -carotene in cell protection against hydrogen
peroxide (H2O2) and nitrogen dioxide radicals (NO•2) (Bohm et al. 2001). Due to the
unique structure of the terminal ring moiety, the terminal ring of astaxanthin is
able to scavenge radicals both at the surface and in the interior of the phospholipid
membrane. The unsaturated polyene chain traps radicals in the membrane (Goto et
al.2001).
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2.1.5.2 Carotenoids as prooxidants
Burton and Ingold (1984) demonstrated first that at high non-physiological oxygen
pressure (pO2 760 mmHg) at a concentration of 500 mM -carotene has prooxidant
behaviour  (Burton  &  Ingold  1984).  The  same  behaviour  was  confirmed  for  -
carotene by Palozza et al. (1997).
Interacting with ROS or reactive nitrogen species (RNS), the carotenoid
molecule is oxidized and/or cleaved to generate products that themselves possess
different, possibly deleterious, activity in biological systems. The presence of high
cellular concentrations of carotenoid alters the properties of a biological membrane
and may increase its permeability to toxins or free radicals. In this particular case,
different carotenoids would be expected to behave quite differently, as they are
incorporated into membranes differently. This may also alter their ability to
interact with ROS or other antioxidants. Interaction with ROS results in the
formation of a carotenoid peroxyl radical, which itself initiates further
lipoperoxidation. The formation of this potentially highly reactive species may be
the consequence of a high carotenoid concentration and/or increased oxygen
tensions (Lowe et al. 2003).
2.1.5.3 Regeneration of carotenoids
It is known that carotenoids can be regenerated from their radical cations formed
during oxidative stress by reacting with tocopherols and tocotrienols (Mortensen &
Skibsted 1997) as described below:
Car•+ + TOH  Car + TO• + H+
  It is possible that tocopherols may react with the carotenoid radical cations
through other means, which may explain why only partial recovery of carotenoids
is observed (Mortensen & Skibsted 1997).
Car•+ + TOH  [CarTO]• + H+
  Recently, isoflavonoid dianions have shown to regenerate carotenoids from
their radical cationic form. Electron transfer to radical cations of -carotene,
zeaxanthin, canthaxanthin, and astaxanthin was found to depend on carotenoid
structures and more significantly on the deprotonation degree of the isoflavonoids.
Electron transfer from isoflavonoids to the carotenoid radical cation, as formed
during oxidative stress, is faster for the astaxanthin radical than for the other
carotenoids (Han et al. 2010). Anionic forms of the conjugated bases of baicalin
have also been found to regenerate the radical cation of -carotene (Liang et al.
2009). Carotenoids can also regenerate each other. It has been shown that lutein
and zeaxanthin are recycled by lycopene. Recycling is more efficient for lycopene
than for -carotene because lycopene is higher in the antioxidant hierarchy
(Mortensen & Skibsted 1997).
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2.1.5.4 Free radicals
Free  radicals  are  atomic  or  molecular  species  that  have  one  or  more  unpaired
electrons in the outer orbital, making them highly reactive. Free radicals can
oxidatively damage nucleic acids, lipids, proteins and carbohydrates (McCall &
Frei 1999), thereby contributing to a number of human degenerative chronic
diseases, including atherosclerosis, cancers and cataracts. However, many chemical
reactions of free radicals form part of the basic chemical processes of normal
human metabolism, such as the regulation of vascular tone, antimicrobial killing,
and regulation of cellular proliferation and growth (Mugge 1998). The human body
possesses specific defense mechanisms to protect against excess formation of free
radicals and from tissue injury. The enzymes, superoxide dismutase (SOD),
catalase, glutathione peroxidase (de Groot 1994), paranoxonase (Aviram et al.
1998), and antioxidants, such as -tocopherol, carotenoids, vitamin C, urate and
thiols, scavenge effectively free radicals, thus protecting the body from oxidative
damage (de Groot 1994).
  Most of the free radicals are derived from molecular oxygen. The term often
used is ROS. This term includes radicals as well as chemicals that can take part in
radical type reactions (i.e., gain or loose electrons) but are not true radicals in that
they do not have unpaired electrons but are often involved in the generation of free
radicals. Examples of non-radical ROS include H2O2, hypochlorous acid (HOCl),
ozone (O3) and singlet oxygen (1O2) (Pryor & Squadrito 1995; Beckman & Koppenol
1996). In addition to oxygen-based radicals, there are also reactive nitrogen species
(RNS), such as nitric oxide (NO) and nitrogen dioxide (NO2) (Darley-Usmar &
Halliwell 1996).
2.1.5.5 Carotenoid reactions with free radicals
Carotenoids are known to lose their color when they react with free radical species.
This phenomenon is explained by degradation of the polyene chain or the addition
of double bonds. There are at least three possible mechanisms for the reaction of
carotenoids with radicals in (Krinsky & Yeum 2003): (1) radical addition, (2)
electron transfer to the radical or (3) allylic hydrogen abstraction.
 1) Radical addition: Burton and Ingold (Burton & Ingold 1984) first proposed the
addition reaction. They suggested that a lipid peroxyl radical (ROO•) might add at
any place across the carotenoid (CAR) polyene chain, resulting in the formation of
a carbon-centered radical (ROO–CAR•). Since this radical would be resonance-
stabilized, it would interfere with the propagating step in lipid peroxidation and
would explain the many examples of the antioxidant effect of carotenoids in
solution (Palozza & Krinsky 1992). The proposed reaction is described in reaction
(1).
CAR + R• R–CAR• (Reaction 1)
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2) Electron transfer: reactions of this type have been reported, resulting either in
the formation of a carotenoid radical such as the cation radical CAR+• the anion
radical, CAR•,  or  in  the  formation  of  an  alkylradical,  CAR•.  For  example,  when
lycopene reacts with the superoxide radical (O2•), electron transfer occurs with the
formation of the anion radical, CAR• (Conn et al. 1992).
CAR + R•  CAR• + + R- (Reaction 2)
 3) Hydrogen abstraction: this process has been suggested by Woodall et al.
(Woodall et al. 1997).
CAR + R•  CAR• + RH (Reaction 3)
  ROS are generated endogenously through normal metabolic process, life style
activities, and diet. They react with critical cellular biomolecules such as lipids,
proteins and DNA and initiate events that lead to increased risk of chronic disease
such as cancer, cardiovascular disease, and osteoporosis (Buico et al. 2009; Milde et
al. 2004).
2.2 CAROTENOIDS AND LIPIDS
2.2.1 The role of oxidized LDL in atherogenesis
LDL is comprised 78% of lipids and 22% of proteins. The main protein molecule in
LDL is apoliporotein B (apoB). Phospholipids and free cholesterol align on the
surface of a particle, while triglycerides and cholesteryl ester are packed in the core
of  the  particle  (Itabe  2009;  Hevonoja  et  al.  2000).  Under  oxidative  stress,  lipid
molecules containing polyunsaturated fatty acids (PUFA) in LDL are oxidized.
During the oxidation process, a variety of lipid oxidation products are formed and
the apoB protein is oxidatively modified, as well. Radical chain reactions on PUFA
lead to the formation of conjugated dienes and lipid hydroperoxides, and
secondary cleavage reactions produce a variety of aldehyde compounds, such as
malondialdehyde (MDA) (Steinberg 2009; Itabe 1998).
  Oxidative modification of LDL is involved in the early development of
atherosclerotic lesions through the formation of macrophage-derived foam cells. It
has been proposed that foam cells could be induced from macrophages after taking
up oxidatively modified LDL (ox-LDL). Macrophages contain receptors for ox-LDL
which can bind and take up ox-LDL. There are more than ten receptors for ox-LDL
in macrophages known as scavenger receptors (Itabe 2003).
  It has been shown that the plasma levels of oxidized LDL are higher in patients
with cardiovascular diseases, such as acute myocardial infarction (AMI). In
addition, increased levels of oxidized LDL were found in patients with carotid
atherosclerosis  (Ehara  et  al.  2001).  A  recent  in  vivo  study  has  provided  evidence
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that ox-LDL can be used to predict future atherosclerotic events (Naruko et al.
2006).  It  has  been  suggested  that  high  ox-LDL  levels  in  the  acute  phase  of  AMI
could be caused by a massive release of ox-LDL from the ruptured plaques,
whereas high levels during the stable phase may indicate that the patients have
strong sources of ox-LDL production. Such sources may include exposure to strong
oxidative stress or the presence of unstable plaques somewhere in blood vessels
that release ox-LDL from the lesions (Itabe 2009).
2.2.2 Effect of carotenoids on oxidative modification of lipids
The effect of carotenoids on lipid peroxidation has been studied in cell cultures
(Table 4). These studies used much higher carotenoid concentrations than the
normal physiological concentrations in human blood circulation. Lipid oxidation
was followed by e.g., copper or 2,2-azobis(2-amidinopropane) dihydrochloride
(AAPH) induced oxidation (susceptibility to oxidation expressed as lag time) or
formation of thiobarbituric acid reactive substances (TBARS). During lag time LDL
is depleted of its antioxidants and after that the rate of lipid peroxidation is rapidly
accelerated (Schreier et al. 1997). These studies are inconsistent, possibly because of
various concentrations of carotenoids and use of various oxidation inducers. In
addition, copper ion concentration in the reaction mixture varied by study. There
are no generally recommended reference methods for lipid oxidation
measurement. Thus, each laboratory can modify the measurements which may
cause variation in the results.
There are numerous intervention studies concerning supplementation of
healthy subjects with carotenoids (capsules) or food stuffs (e.g., tomato products),
in which effects of carotenoids on lipid oxidation are evaluated (Table 5 and Table
6). Oxidative modification of lipids was followed e.g., by copper/AAPH induced
oxidation (susceptibility to oxidation expressed as lag time) or measuring TBARS,
F2 free isoprostanes or MDA. Copper or AAPH -induced methods are in vitro lipid
oxidation measurements, whereas in vivo formed F2 isoprostanes or MDA reflect
better the lipid oxidation in the body. The traditionell, but quite unspecific, TBARS
measurement, in principle, is an in vivo measurement, but the high temperature
needed for the reaction may cause in vitro formation of TBARS in the sample. Of
the four latest placebo controlled studies, two showed decreasing lipid oxidation
after astaxanthin or combined -carotene, lycopene and lutein supplementation,
but in two controlled studies and in uncontrolled studies there were no effect
(Table 5). Neither effect has been found in the latest controlled dietary
supplementation studies (Table 6). However, most of the dietary supplementation
studies have been uncontrolled leading to quite uncertain results. It seems that
most of intervention studies studies do not support the protective role of
carotenoid supplementation against lipid oxidation.
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Table 5. Effect of carotenoid supplementation on LDL oxidation in healthy humans. Latest most important studies.
Carotenoid Dose (mg/d)                                                    Effect on LDL
supplementation and duration           N         Measurement          oxidation              Reference
-Carotene              50-100 mg 16 Lag timea  No effect (Gaziano et al. 1995)
(uncontrolled) for 3 weeks                      (1.25 μM Cu2+and
                                                                          4 μM AAPHb)
Lycopene 13.3 mg       51 Lag time        No effect          (Carroll et al. 2000)
-Carotene 8.2 mg                               (15 μM Cu2+)
-Carotene 3.7 mg
(Placebo controlled)   for 12 weeks
Astaxanthin 1.8-21.6 mg 24 Lag time                    (Iwamoto et al. 2000)
(Placebo controlled) for 14 days                     (400 μM MeO-AMVN)c
-Carotene 15 mg 175 Lag time  No effect (Hininger et al. 2001)
Lycopene 15 mg                                (2.5 μM Cu2+)
Lutein 15 mg
(Placebo controlled) for 3 months
-Carotene 6 mg                      32            Lag time                    (Kioskias & Gordon 2003)
-Carotene 1.4 mg                                  (5 μM Cu2+)
Lycopene 4.5 mg
Lutein 4.4 mg
(Placebo controlled)  for 3 weeks
-Cryptoxanthin 1.3 mg 12 Lag time                   No effect             (Wolters & Hahn 2004)
(uncontrolled) for 24 h (20 μM Cu2+)
Resistance to isolated LDL to copper/AAPH induced oxidation measured by spectrophotometer. aTime to maximal
oxidation rate, b 2,2-azobis(2-amidinopropane) dihydrochloride, c 4-methoxy-2,4-dimethylvaleronitrile,  Decrease
oxidative modification of LDL, N = number of subjects
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Table 6. Summary of latest dietary intervention studies in healthy humans.
 Dietary      Dose  Effect on lipid
 Supplementation and duration                N        Measurement         oxidation              Reference
Tomato juice One week of   19            Lag timea  (Agarwal & Rao 1998)
Tomato sauce each (Cu2+)
Tomato oleoresin   LDL-TBARSb
(Cross-over)
Lycopene, ~300-400 g   34     Lag time  (Chopra et al. 2000)
-carotene and 4 weeks ( 11.7 μM Cu2+)
lutein rich foods
(Cross-over)
Vegetables, 170-815 g   77 Plasma and LDL-  No effect (Freese et al. 2002)
berries and (lutein, cryptoxanthin,      TBARS
apples lycopene, -carotene               Lag time (5 μM Cu2+)
(Control group) and -carotene)                         F2 isopostanes
c
for 6 weeks
Tomato products ~585 g for   31    Lag time  (Ahuja et al. 2003)
and guava 14-16 days (1 mM Cu2+)
(Cross-over)
Tomato products Fresh tomato 100 g        12           Lag time                     (Visioli et al. 2003)
with olive oil Sauce 60 g (5 μM Cu2+)
(Cross-over) Paste 15 g  F2 isoprostanes
c
                              each for 3 weeks
Tomato or carrot 330 ml   22   Lag time    No effect (Briviba et al. 2004)
juice for 2 weeks (20 μM Cu2+)
(Cross-over)     MDAd
Soups and 400 g for 4 weeks   36    Lag time No effect (Paterson et al. 2006)
beverages of ( 1.66 μM Cu2+)
fruits and
vegetables
(Control group)
Lutein + 12 mg            40   MDA No effect             (Li et al. 2010)
green tea extract 200 mg
(Cross-over) for 4 weeks
Resistance to isolated LDL to copper induced oxidation measured by spectrophotometer. a Time to maximal
oxidation rate, e Thiobarbituric acid reactive substances, c Lipid peroxidation products of arachidonic acid,
d Malondialdehyde,  Decrease oxidative modification of lipids, N = number of subjects
2.2.3 Epidemiological evidence on cardiovascular diseases
Over the last 20 years, many interesting studies have been published concerning an
association between the intake of carotenoids and risk of cardiovascular diseases
(CVD). The largest studies include the Health Professionals Follow-Up Study
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(HPFS) (Rimm et al. 1993), a study of approximately 40000 male health
professionals, and the Nurse’s Healthy Study (NHS) (Osganian et al. 2003), a study
of approximately 80000 female nurses. The HPFS study found an inverse
association with CVD risk among current smokers (RR=0.30; 95% CI: 0.11–0.82) by
comparing the highest quintile of dietary carotene intake to the lowest. For former
smokers, RR was 0.6, and the risk was nonsignificant for nonsmokers. In the NHS,
the relationship between dietary  intake  of  carotenoids  and  the  risk  of  coronary
artery disease (CAD) was studied in 73286 female nurses using a semi-quantitative
food-frequency questionnaire. During the 12-year follow-up, they identified 998
incident cases of CAD and modest, significant, inverse associations between the
highest quitiles of -carotene (7.6 mg) and -carotene (1.5 mg) intakes and the risk
of CAD was observed, but not with lutein plus zeaxanthin, lycopene,  or  -
cryptoxanthin intakes.
  The large Physicians' Health Study identified 499 cases of CVD during a mean
follow-up of 2.1 years. Plasma lycopene was not associated with a risk of CVD in
middle-aged and older men (RR=1.03; 95% CI: 0.65–1.64) (Sesso et al. 2005),
whereas plasma lycopene was inversely related to a risk of CVD in women (Sesso
et al. 2004). In a case-control study in Milan, Italy, examining 760 patients with
nonfatal acute myocardial infarction (AMI) and 682 controls, the risk of AMI
decreased with increasing daily intake of -carotene (684 μg), -carotene (4186 μg)
and  -cryptoxanthin  (340  μg).  No  associations,  however,  were  observed  for  total
carotenoids, lycopene, lutein plus zeaxanthin and retinol (Tavani et al. 2006).
  Fifteen cohort studies were included in a meta-analysis consisting of 7415
incident coronary heart disease (CHD) cases and 374,488 participants with a
median follow-up of approximately 10, 8.5, and 15 years for intake from diet or
supplements of vitamins C, E, and -carotene, respectively. The combined RR in
the highest tertile of -carotene intake as compared to the lowest tertile for CHD
was 0.78 (95% CI: 0.53–1.04). Findings of the meta-analysis suggested that an
increase in the dietary intake of -carotene has encouraging prospects for possible
CHD prevention (Ye & Song 2008). In another pooled cohort analysis, during a 10-
year follow-up, 4647 major incident CHD events occurred in 293172 subjects free
from CHD at baseline. Of the individual carotenoids, lutein intake was significantly
inversely associated with CHD incidence (RR=0.89; 95% CI: 0.75–1.04; P for
trend=0.03), whereas the strength of association for the other carotenoids was
nonsignificant. The results suggested that a higher dietary intake of lutein reduces
the risk of CHD (Knekt et al. 2004).
  In  a  recent  study,  it  was  determined  whether  low  plasma  carotenoids  are
associated with increased all-cause mortality among older adults. In a multivariate
Cox proportional hazards model, adults in the highest tertile of plasma carotenoids
at enrollment had lower mortality compared to those in the lowest tertile (Hazards
Ratio 0.81, 95%; CI: 0.65–0.99; P for trend = 0.046). The results suggested that low
plasma carotenoids are an independent risk factor for mortality among older
adults (Lauretani et al. 2008). In the Zutphen Elderly Study in the Netherlands,
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dietary intakes of -carotene and -carotene were inversely associated with CVD
mortality in elderly men after a 15-year follow-up. Intake of - and -carotene was
associated  with  ~20%  lower  risk  ratio  (RR)  of death from CVD. The multivariate-
adjusted RR was 0.72 (95% CI: 0.57–0.90) for -carotene and 0.74 (0.60–0.91) for -
carotene. The RR for the consumption of carrots was 0.83; 95% CI: 0.68–1.00
(Buijsse et al. 2008).
2.3 CAROTENOIDS AND CANCER
2.3.1 The role of carotenoids in carcinogenesis
Carcinogenesis is the process by which normal cells are transformed into cancer
cells.  Mutations  in  DNA  leading  to  cancer  disrupt  the  balance  between
proliferation and programmed cell death (apoptosis). A series of several mutations
in certain classes of genes is usually required before a normal cell transforms into a
cancer cell. The uncontrolled and often rapid proliferation of cells can lead to
benign tumors, some of which may turn into malignant tumors (Kleinsmith 2006).
Although lifestyle and dietary factors are known to be important in preventing
cancer, the mechanism still remains unclear (Kushi et al. 2007; Correa Lima &
Gomes-da-Silva 2005). ROS produced in cells, largely as a consequence of
metabolic processes, constantly threatens the integrity and correct functioning of
cellular DNA (Lindahl 1993). Several oxidants have the capacity to produce pro-
mutagenic lesions in DNA (Shibutani et al. 1991), which may play a significant role
in the development of cancer.
 Carotenoids may protect against carcinogenesis by scavenging of DNA-
damaging free-radicals, induce enzymes (e.g., cytochrome P450) that are involved
in the metabolism of several carcinogens, affect on cell proliferation, cell
differentiation, gap-junctional cell communication and enhance the immune
system (Astorg 1997, Bhuvaneswari & Nagini 2005). It has been shown that at
physiological concentrations, lycopene inhibit the growth of normal human
prostate epithelial cells in vitro, which may prevent a benign prostate hyperplasia,
a risk factor for prostate cancer (Obermuller-Jevic et al. 2003). In a previous study,
lycopene and hexane extract of tomato paste inhibited cell gwroth in a dose-
dependent manner (0.1-50 μmol/l of lycopene) (Hwang & Bowen 2005).
Interference in androgen metabolism, and inhibition of growth factors and
cytokine activity, appear to be the major pathways through which lycopene
inhibits prostate and breast cancer growth (Karas et al. 2000).
 In  addition  to  lycopene,  other  carotenoids,  such  as  lutein  -carotene  and  -
cryptoxanthin have shown a strong anti-carcinogenic activity in animal screening
tests (Nishino et al. 2009). -Carotene has shown higher activity than -carotene in
suppressing tumorigenesis in skin, the lungs, liver and colon. In the skin
tumorigenesis experiment, the average number of tumors in per mouse was
significantly smaller in the -carotene group than in the control group. -Carotene
treatment also decreased the development of tumors, though the difference
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between the treatment and control groups was not significant (Nishino et al. 2009).
The  ferret  and  mouse  lung  cancer  models  have  been  used  to  investigate  the
mechanism of interaction of -carotene with carcinogens in the lung. No effects or
even protective effects against smoke or carcinogen exposure were observed when
-carotene was applied at physiological doses or in combination with vitamins C
and E (Goralczyk et al. 2009). Lorenzo et al. (Lorenzo et al. 2009) reported a clear,
dose-dependent antioxidant-protective effect for -cryptoxanthin that decreased
the damage to DNA induced by H2O2.
2.3.2 Carotenoid supplementation and cancer biomarkers
Supplementation of carotenoids may have beneficial effects against cancer
development and progression, although the results have been inconsistent. A pilot
study investigated the effects of lycopene supplementation in elderly men
diagnosed with benign prostate hyperplasia (BPH), who were at increased risk of
developing prostate cancer. The 6-month lycopene supplementation (15 mg/d)
decreased prostate specific antigen (PSA) levels, whereas no change was identified
in the placebo group. The study indicated that lycopene may inhibit disease
progression and may ameliorate symptoms in BPH patients (Schwarz et al.  2008).
Lycopene intake before prostatectomy has been reported to decrease serum
concentrations of PSA and growth of tumors in patients with clinically localized
prostate cancer (Kucuk et al. 2001; Chen et al. 2001). A dose of -carotene (50 mg)
on  every  second  day  had  neither  significant  effect  on  the  molecular  markers  of
lung carcinogenesis (cytochrome p450 enzyme 1A1 (CYP1A1)) nor on the risk of
developing lung cancer (Liu et al. 2009).
2.3.3 Epidemiological evidence on cancer
Of  all  the  cancers,  the  effect  of  lycopene  on  the  reduction  of  prostate  cancer  has
received the most attention (Rao & Rao 2007) (Table 7). An inverse relationship
between tomato intake and the risk of prostate cancer was first reported by
Giovannucci et al. (Giovannucci et al. 1995). In two previous studies (in Table 7), an
inverse association between blood lycopene concentration and the risk of prostate
cancer has been observed (Lu et al. 2001; Zhang et al. 2007). Results from a meta-
analysis of 11 case-control studies and 10 cohort studies reported a 10% to 20%
reduction in prostate cancer risk, though this effect was restricted especially to
above 200 g/d of tomato intake (Etminan et al. 2004). Seren et al. 2008 have
proposed in their review that the association between the reduced risk of cancer
and intake of tomatoes, tomato-based products and blood levels of lycopene is
strongest for prostate cancer. The U.S. Food and Drug Administration (FDA) have
found only limited credible evidence for tomato intake and a reduced risk of
prostate cancer, but not for lycopene intake (Kavanaugh et al. 2007).
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A recent review suggested a strong protective effect of lycopene intake and plasma
levels of lycopene against gastric and colon cancer, and a weaker effect for cancers
of  the  pancreas  and  oral  cavity  (Seren  et  al.  2008).  The  FDA  found  no  credible
evidence to support an association between tomato or lycopene intake and a
reduced risk of lung, colorectal, cervical, gastric, breast, ovarian, endometrial, or
pancreatic cancer. The FDA found very limited evidence to support an association
between tomato consumption and reduced risks of ovarian, gastric, and pancreatic
cancers  (Kavanaugh  et  al.  2007).  A  recent  report  by  the  World  Cancer  Research
Fund stated that foods containing lycopene probably protect against prostate
cancer (World Cancer Research Fund/American Institute for Cancer Research
2007).
  Two of the latest three meta-analyses found an association between decreased
risk or renal or lung cancer and dietary intake of carotenoids or carotenoid
containing food stuff (Table 8).
  In Table 9, we can see that -carotene, -carotene and lycopene are the
carotenoids, which are most abundant in plasma sample and thus most often used
for  risk assessment  in  epidemiological  studies.  It  has  been shown that  plasma -
carotene was inversely associated with the risk of gastric cancer (Persson et al.
2008) and colorectal cancer (Jiang et al. 2005). In another study, plasma -
cryptoxanthin and zeaxanthin were associated with reduced risk of gastric
adenoma (Jenab et al. 2006). In American case-control study, plasma carotenoids
except lycopene were inversely associated with the risk of bladder cancer (Hung et
al. 2006). However, in a previous study, high plasma lycopene concentrations were
associated with decreased mortality of oral, pharynx or larynx cancers (Mayne et
al. 2004). Meta-analysis showed that serum carotenoids may not protect from the
risk of lung cancer (Gallicchio et al. 2008).
  In a carotenoid supplementation studies (Table 10), the risk of total cancer
decreased in men by using a combination of vitamin C, vitamin E and -carotene
(Galan et al. 2005). Interestingly, previous studies have observed either increased
risk or no effect on various cancers using§ combinations of carotenoids.
2.4 ANALYSIS OF CAROTENOIDS
2.4.1 Sample collection and storage
There are many reports dealing with the stability of carotenoids in biological
samples. Su et al. (Su et al. 2002) observed that there were no significant changes in
the concentrations of lutein/zeaxanthin, -cryptoxanthin, -carotene and -
carotene, except for lycopene, in whole blood stored at +4°C in the dark. At room
temperature, during exposure to light, the concentrations of carotenoids still
remained stable, though the reduction in lycopene concentration was significant.
All carotenoids were unstable at +35°C. The chemical structure of carotenoids
makes them potentially susceptible to oxidative damage or isomerization with
exposure to oxygen, light, or heat (Clark et al. 2004). It has been reported that
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 exposure to indoor light, but not outdoor light, before processing or replacing air
 in vials with nitrogen gas did not alter concentrations substantially (Clark et al.
2004), suggesting that normal processing methods are acceptable for carotenoids.
  Serum and plasma carotenoid concentrations were reported to be stable at -
20°C for 5-9 months. Comstock et al. reported that -tocopherol and carotenoids
were all stable at -77°C for 4 years in plasma (Comstock et al. 1993). Thomas et al.
found no evidence of degradation of retinol, -tocopherol, and -carotene in
lyophilized serum, when stored at -80°C over the 10-year period (Thomas et al.
1998). By contrast, it was  found that carotenoids, -tocopherol and -tocopherol in
plasma stored at -80°C were stable only for up to 8 months (Peng et al. 1994).
  It has been observed that carotenoids become unstable after being extracted
from plasma into organic solvents, particularly on exposure to light and heat. The
stability of carotenoids extracted from plasma into hexane containing 0.01% BHT
was  investigated  at  different  temperatures  (Su  et  al.  1999).  Variability  in  the
measurement of lutein/zeaxanthin, -cryptoxanthin, trans-lycopene, -carotene
and -carotene was  greater  at  room  temperature  that  at  either  +4°C  or  -20°C.
Statistically significant variations were observed in the measured concentrations of
lutein/zeaxanthin, -carotene and -carotene in samples kept cold. However, the
concentration decrease was small and of little biological significance, particularly
over  the  first  24  h.  At  room  temperature,  the  variability  of  concentrations  was
greater than in samples kept cold. Thus, storage of extracts at room temperature is
not recommended (Su et al. 2002; Su et al. 1999).
2.4.2 Chromatographic methods
Methods based on chromatography involve physical separation in which
carotenoids are distributed between two phases (stationary and mobile phase). The
stationary phase may be solid or liquid. The mobile phase may be liquid or gas.
HPLC, which has a liquid mobile phase, is the most popular analytical method for
measuring  carotenoids  from  biological  materials.  Gas  chromatography  (GC)  has
been rarely used for analysis of carotenoids, because these compounds are labile to
destruction and isomerization at high temperatures, and they are not very volatile
(De Leenher et al. 2000).
2.4.2.1 Sample preparation for chromatography
Carotenoids are usually soluble in lipids or in non-polar solvents, except when
they exist as complexes with proteins and sugars. The most common method for
sample purification is liquid-liquid extraction. In these methods, blood plasma or
serum is often first treated with a polar solvent (usually ethanol) to precipitate
proteins  and  then  fat-soluble  vitamins  (e.g.,  retinol  and  tocopherols),  and  the
carotenoids are extracted with hexane or ethyl acetate. Diethyl ether is also used
for extractions. An internal standard is often dissolved in the organic solvent used
to precipitate proteins. It is also necessary to add antioxidants such as butylated
hydroxyanisole (BHA) or butylated hydroxytoluene (BHT) during the extraction
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process to prevent degradation of the carotenoids (Su et al. 2002). Hexane is the
organic solvent most commonly used for the extraction of carotenoids from
biological fluids (Olmedilla-Alonso et al. 2005; Lee et al. 2003; Lyan et al. 2001;
Talwar et al. 1998; Gueguen et al. 2002). Thurnham et al. (1988) extracted
carotenoids from plasma with heptane (Hexane does not carry water from the
serum  and  is  easy  to  evaporate  under  a  gentle  stream  of  nitrogen  or  argon.  The
organic extracts of plasma or other biological samples are usually concentrated to a
known volume of suitable solvent before chromatographic analysis. Solid-phase
extraction is also used to purify carotenoids from biological fluids prior to
chromatographic  analysis.  The  sample  is  added  into  an  activated  mini-column
containing the stationary phase (usually derivatized silicagel). Proteins and other
sample components are washed away and the carotenoids are finally eluted from
the  column  with  a  suitable  solvent.  Dueker  et  al.  (1993)  used  a  C18 silica-based
sorbent for the separation of retinol from its aqueous matrix followed by removal
of  lipid  contaminants  with  an  aminopropyl  silica-based  sorbent.  In  2004,
Chatzimichalakis et al. (2004) published a method using cyclohexyl columns for
purifying carotenoids from blood serum and urine. A fully automatic method was
developed for the determination of carotenoids in serum. In that method, a sample
was injected into an automatic solid phase extraction (SPE) system for cleanup and
pre-concentration, and then on-line transferred to a reversed-phase analytical
column (Chatzimichalakis et al. 2004).
2.4.2.2 High performance liquid chromatography
Carotenoids are separated by their partition coefficient between the solid phase of
the column and the HPLC eluent. Most of the HPLC methods for carotenoids are
isocratic, but the separation efficiency can be improved by using gradient elution.
The gradient is often based on an organic solvent.
  Normal-phase liquid-chromatography methods are rarely used for measuring
the serum and plasma concentrations of carotenoids. In a normal-phase system, the
stationary  phase  is  more  polar  than  the  mobile  phase.  McGeachin  et  al.  (1995)
published a normal phase HPLC method employing a hexane: ethyl acetate mobile
phase gradient for separating and quantifying vitamin A and E and carotenoids
from serum (McGeachin & Bailey 1995). Khachik et al. (1997) analyzed carotenoids
and their metabolites from human milk and serum by using a silica-based, nitrile-
bonded column and a mobile phase consisting of hexane:
dichloromethane:methanol:N,N-diisopropylethylamine (Khachik et al. 1997).
However, this normal-phase system requires a large volume of organic solvent
waste.
  Reversed-phase separation phases have been commonly used for HPLC
carotenoid analysis. For clinical purposes and large epidemiological studies using
human  plasma,  reversed-phase  HPLC  with  ultraviolet  (UV)  detection  using
octadecylsilyl (C18) column is an optimal approach. It is quick, simple, relatively
cheap, shows good recovery (90–105%), low limits of detection  and has good
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reproducibility (inter-assay coefficient of variation (CV) <10%). In these systems,
the mobile phase is more polar than the stationary phase (Su et al. 2002). With
reversed-phase HPLC, octylsilyl (C8)  and  C18 columns have proved to be well
suited for analysis of carotenoids (Su et al.  2002). Most of the published methods
have used a C18 HPLC column (e.g., Olmedilla-Alonso et al. 2005; Lee et al. 2003;
Lyan et al. 2001; Talwar et al. 1998; Gueguen et al. 2002; Nierenberg & Nann 1992;
Ortega et al. 2004). HPLC methods based on C8 stationary phases are not common
(Huck et al. 2000). Triacontanylsilyl (C30) bonded columns are a good choice for
analysis of carotenoids as well as mixtures of their geometrical isomers (Schweigert
et al. 2003, Rajendran et al. 2005).
  UV and visible single wavelength absorbance detectors have been used for
many years  as  components  of  HPLC systems for  quantitation of  carotenoids.  UV
absorbance detection allows sufficient sensitivity for many routine purposes.
Coupling a diode array detector (DAD) to the HPLC allows for a continuous
collection of spectrophotometric data during analysis (Su et al. 2002), which greatly
aids in determining peak purity and identifying unknown compounds in some
cases. In addition, fluorescence detectors (Lee et al. 2003), electrochemical detectors
(Finckh et al. 1999, Hermans et al. 2005; Lee & Ong 2009) and mass spectrometry
(Khachik et al. 1997; Wang et al. 2000; Kelm et al. 2001,; Andreoli et al. 2004) have
been used with HPLC to analyze retinol, tocopherols, tocotrienols, carotenoids and
their isomers from human blood.
2.4.2.3 Other methods based on chromatography
Open-column and thin-layer chromatography methods were originally used for
analysis of carotenoids. Historically, much of the “carotene” data in tables of food
composition has been obtained by measuring absorption at a specified wavelength
and quantified against a -carotene standard, or more commonly by open-column
chromatography to separate carotenoid pigments, which are then quantified
spectrophotometrically. Open-column and thin-layer chromatography methods
require large amounts of sample and have difficulties with total recovery of the
carotenoids from thin layer chromatography (TLC) plates. These methods, clearly
offer poorer resolution and assay speed than more modern methods (Su et al.
2002).
  Sander  et  al.  (Sander  et  al.  1994)  first  reported  the  use  of  polymeric  C30
stationary phases  in  capillary electrochromatography (CEC) for  the separation of
carotenoid isomers in foods and algaes. Isocratic CEC separations were carried out
using a Hewlett-Packard 3D capillary electrophoresis instrument with vial
pressurization modification. Absorbance detection at 450 nm was employed with
acetone and a  1  mM borate  buffer  as  the mobile  phase.  This  method was able  to
separate from food samples lycopene isomers, -carotene isomers, -carotene
isomers, lutein isomers, zeaxanthin isomers and -cryptoxanthin isomers (Sander
et al. 1994).
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2.4.3 Other techniques
The new Optothermal Window (OW) method was developed for measuring
lycopene  in  tomato  products.  This  method  appeared  to  be  a  reliable,  quick
analytical tool for determining the concentration of lycopene from a large variety
of commercial tomato products without sample purification (Bicanic et al. 2004).
Hornero-Méndez et al. (2001) published a method for determining red and yellow
carotenoid pigments from paprika and red pepper oleoresins based on UV-visible
spectrophotometry. Wavelengths of 472 and 508 nm were used for simultaneous
quantification of these pigments from the acetone extract (Hornero-Mendez &
Minguez-Mosquera 2001).
3 Aims of the study
The aims of the present study were:
1. To develop a quick, simple and sensitive method for analyzing plasma
concentrations of retinol, -tocopherol, lutein, zeaxanthin, -cryptoxanthin,
lycopene, -carotene and -carotene.
2. To investigate and follow the plasma levels of carotenoids and fat-soluble
vitamins in Eastern Finnish men and women from the late 1980s to the
beginning of the 2000s, and the seasonal variation in carotenoid levels.
3. To investigate the effects of astaxanthin supplementation on lipid oxidation
in healthy men by using various lipid oxidation markers.
4. To identify the main determinants of serum LDL conjugated dienes (focus
on carotenoids, retinol and -tocopherol).
5. To study the association between serum concentration of lycopene and the
risk of cancer among eastern Finnish, middle-aged men in the Kuopio
Ischaemic Heart Disease Risk Factor (KIHD) study.
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4 Materials and methods
4.1 STUDY SUBJECTS AND DESIGN
4.1.1 HPLC method development (I)
The subjects used in the development of the carotenoid measurement method were
male volunteers from the Laboratory of the Research Institute of Public Health of
University of Kuopio. Part of the subjects used in comparing the method, were
from Spain.
4.1.2 Astaxanthin Supplementation Study (ASTA, II)
The study subjects were healthy non-smoking male volunteers aged 1933 years
with no severe diseases or malabsorption. The study was a randomized double-
blind trial based on comparison of two parallel identically sized groups; the
intervention group received 4 mg of astaxanthin (Astaxin, AstaReal AB, Sweden)
capsules twice per day (N=20) and the placebo group two identical-looking placebo
capsules (microcrystalline cellulose) (N=20).
4.1.3 Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study (III, IV)
The KIHD is an ongoing population-based, cohort study that was designed to
investigate risk factors for cardiovascular and other degenerative disease in a
sample of middle-aged men in the city of Kuopio, Finland and its rural
communities. Baseline examinations of men aged 4260 were carried out between
1984 and 1989. Of the 3235 eligible male subjects, 2682 (82.9%) participated in the
study. Baseline examinations of women aged 5373 years were carried out between
March 1998 and February 2001. Of 1173 eligible female subjects, 920 (78.4%)
participated in the study. After the baseline, 696 had died and 1031 had severe
illness, migrated from the area, refused, or could not be contacted. Thus, 1241 men
and 634 women aged 61-80 years participated in this 20-year follow-up visit over
the years 2005-2008. For study III, samples for serum LDL conjugated dienes and
plasma carotenoids were collected and analysed from a randomly selected
subgroup of 349 subjects (124 women and 225 men) during February-October, 2007
and January-March, 2008.
  Four-year  reexaminations  (i.e.,  the  entry  for  study  IV)  for  those  examined  in
1986-1989 were conducted between March 1991 and December 1993. Data for
testing the association between serum concentrations of lycopene and the risk of
cancer among Eastern Finnish middle-aged men were available for 997 men.
 To assess possible changes in the serum levels of carotenoids over about 20
years in the Eastern Finnish population, serum/plasma carotenoid concentration
were measured in the KIHD subjects. Concentrations were measured from men in
the 4 y reexamination visit during the years 1991-1993 (N=1031), 11 y
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reexamination during the years 1998-2001 (N=851) and in the so-called 20 y
reexamination during the years 2005-2008 (N=1228), with the follow-up time
ranging between 16-24 years. However, the 20 y visits were carried out at the same
quarter of the year as the baseline examinations. In women, the concentrations
were measured at the baseline visit during the years 1998-2001 (N=913) and at the 7
y reexamination during the years 2005-2008 (N=620).
4.1.4 Permission of the Ethics Committee
The Ethics Committee of the Northern Savo Hospital District accepted the
substudies II-IV for this thesis.
4.2 Blood sampling (I, II, III, IV)
Subjects were instructed to abstain from eating and smoking for 12 hours (I, II, III,
IV)  and  from  consuming  alcohol  for  2  days  (II,  III)  or  3  days  (IV)  before  blood
sampling. Fasting venous blood samples were collected into vacuum tubes
(Terumo,  Leuven,  Belgium) without  tourniquet  after  the subject  had rested in  the
supine position for 5 min (I, II, III) or 30 min (IV). Blood samples were centrifuged
at 1500 × g for 10 min after collection, and serum or plasma was separated
immediately after centrifugation. Blood for carotenoids was collected in lithium
heparin tubes (I, III) that were kept on ice until centrifugation and serum tubes (IV)
and  EDTA  tubes  (II).  Frozen  samples  were  stored  at  70/-80°C  until  used.  The
blood cell profile was analysed from fresh EDTA blood (II, IV). Blood for the
measurement  of  LDL  conjugated  dienes  (III)  was  drawn  into  serum  tubes,  and
samples  were  centrifuged  at  1500  ×  g  for  10  min  within  30  min  after  blood
collection. After separation of serum, 12 μl of 100 mg/ml EDTA was added to 1.2
ml of serum to avoid ex vivo oxidative modification of LDL and an analysis was
performed immediately from the fresh sample.
4.3 Analysis of astaxanthin, other carotenoids and vitamins
For the original publication II, plasma astaxanthin and other carotenoids (lutein-
zeaxanthin, canthaxanthin, lycopene, -cryptoxanthin and -carotene) were
determined by Professor Anders Olsson in Uppsala, Sweden. In the original work
IV,  an HPLC method based on the method by Thurnham et  al.  (Thurnham et  al.
1988) was used for the determination of retinol, -tocopherol and -carotene serum
concentrations. This method lacks lutein-zeaxanthin, canthaxanthin and -
cryptoxanthin.
The HPLC method for determination of plasma carotenoids (lutein, zeaxanthin,
-cryptoxanthin, lycopene, -carotene and -carotene) and fat-soluble vitamins
(retinol and -tocopherol) developed in work I was also used in work III.  Briefly,
the frozen Li-heparin plasma samples were thawed at room temperature and 200
μl  was pipetted into glass  tubes.  A volume of  500 μl  of  ethanol-0.01% (w/v)  BHT
containing -tocopherol acetate and -Apo-8'-carotenal as internal standards, was
added. Thereafter, water and hexane were added and samples were extracted. The
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samples were centrifuged at 1500 × g for 5 min at +4°C and frozen at -70°C for 30
min. The upper organic layer was  decanted  into  a  glass  tube  and  evaporated  to
dryness under a gentle stream of nitrogen at room temperature. The dried residue
was reconstituted in 200 μl of the mobile phase into the HPLC. In work III, lipid
standardized values of retinol and -tocopherol (Jordan et al. 1995) were used for
statistical analyses.
  Ascorbic acid was analysed by high-performance liquid chromatography using
the ion-exchange method (Parviainen et al. 1986) (II).
  Serum folate was measured by using a radioimmunoassay (Quantaphase II;
Bio-Rad, Hercules, CA) (Rissanen et al. 2001).
4.4 MEASUREMENT OF LIPID OXIDATION IN VITRO AND IN VIVO
4.4.1 LDL and VLDL to oxidation in vitro (II)
Combined VLDL and LDL were isolated from fresh ethylene diamine tetra-acetic
acid (EDTA) plasma by density gradient ultracentrifugation (KBr gradient). Since
EDTA blocks the lipoprotein reaction with Cu2+, EDTA was removed from the LDL
fraction by using small gel filtration PD-10 columns (Pharmacia, Uppsala,
Sweden). Briefly, VLDL+LDL fraction was diluted with oxygen-saturated
phosphate buffered saline and the formation of conjugated dienes was initiated by
adding copper chloride to the diluted VLDL+LDL fraction and the reaction was
followed by spectrophotometry at 234 nm (Kaikkonen et al. 1997; Nyyssönen et al.
1997). The lag time, and the maximum reaction velocity (Vmax) were determined at
+37°C by a temperature controlled Beckman Du 640i spectrophotometer with an
enzyme kinetics data system (Beckman Co, Brea, CA, USA).
4.4.2 Plasma hydroxy fatty acids and free F2-isoprostanes (II)
Plasma (Li-heparin) C18 hydroxy fatty acids (8, 9, 10, 11, 12, 13, 15 and 16-mono
hydroxy fatty acids) (Wilson et al. 1997) as well as plasma free F2-isoprostanes were
measured using a gas chromatograph/mass spectrometer (Agilent Technologies,
Espoo, Finland) (Morrow et al. 1999).
4.4.3 Serum LDL conjugated dienes (III)
The content of conjugated dienes in precipitated LDL was determined
spectrophotometrically. Briefly, serum LDL was precipitated with buffered
heparin,  and  resuspended  in  0.1  M  phosphate  buffered  salin,  pH  8.0.  The
cholesterol concentration was determined, and the rest of the suspension was used
for  measuring  conjugated  dienes.  Lipids  were  extracted  from  the  LDL  with  a
mixture of chloroform: methanol (3:1), evaporated to dryness with a gentle stream
of nitrogen, and reconstituted in cyclohexane. The concentrations of conjugated
dienes were measured spectrophotometrically at 234 and 300 nm.
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4.4.4 Other biochemical measurements (II, III, IV)
Serum  paraoxonase  (PON)  activity  was  measured  based  on  its  capacity  to
hydrolyze  paraoxonase  on  a  microtiter  plate  (Thermo  Electron  Oy,  Vantaa,
Finland) (Mackness et al. 1991). Uric acid was measured using an enzymatic
colorimetric method (Randox Laboratories Ltd, UK).
  Concentrations of serum interleukin 6 and interleukin 2-receptor were
analysed by a solid-phase Enzyme Amplified Immunoassay on a microtiter plate
(BioSource Europe SA, Nivelles, Belgium). Plasma C-reactive protein (CRP) was
determined with a high sensitivity particle-enhanced immunoturbidimetric assay
(CRP Latex HS, Roche/Hitachi 911, Roche Diagnostics GmbH, Mannheim,
Germany).
  Concentrations of serum total cholesterol (Konelab 20XT, Thermo Fisher
Scientific, Vantaa, Finland) and triglycerides (Roche Diagnostics, Mannheim,
Germany) were analyzed with enzymatic methods. Serum HDL cholesterol was
measured from the supernatant after magnesium chloride dextran sulfate
precipitation with enzymatic method (Thermo Fisher Scientific), and the enzyme
activity of serum gamma-glutamyl transferase (-GT) with the method
recommended by International Federation of Clinical Chemistry and Laboratory
Medicine (Thermo Fisher Scientific). Blood glucose was measured using a
hexokinase method (Thermo Fisher Scientific) after precipitation proteins by
trichloroacetic acid. Leukocytes were analyzed by Advia 60 blood cell counter
(Siemens Healthcare Diagnostics, Deerfield, IL, USA).
  Serum fatty acids were analyzed after chloroform-methanol extraction and
methylation with sulphuric acid–methanol. The methylated fatty acids were
analyzed by a gas chromatograph equipped with a flame ionization detector.
4.4.5 Assessment of nutrient intake (II)
The consumption of foods was assessed at the time of blood sampling during the
baseline phase and at the end of this study. Subjects were instructed on the use of
household measures for quantitative recording of  their  food  intake  during  the  4-
day data collection. A nutritionist gave instructions and checked the completed
food intake records. Dietary intake of nutrients and foods was calculated using
NUTRICA software (version 2.5; The Social Insurance Institution of Finland,
Turku, Finland). This software is compiled using mainly Finnish values for the
nutrient composition of foods, and takes into account the losses of vitamins in food
preparation. In total, the database contains comprehensive data for 1300 food items
and dishes, as well as 30 nutrients (Rissanen et al. 2003).
4.4.6 Other measurements (II, III, IV)
The waist-to-hip ratio was defined as the circumference of the waist girth/hip
measured  at  the  trochanter  major.  The  body  mass  index  (BMI)  was  computed as
the ratio of weight (kilograms) to the square of height (meters). Alcohol ingestion
was assessed with a questionnaire structured quantity-frequency method on
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drinking behaviour over the previous 12 months. Education was coded into three
categories  based  on  years  of  education  (<6,  7-11,  and  12  or  more  years).  Family
history of cancer was asked by a self-administered questionnaire and checked by
the interviewer (Laukkanen et al. 2004). Physical activity was assessed using a 12-
month leisure-time history based on self-reported information about frequency per
month over the preceding year, average duration per occasion, and intensity level.
Metabolic units were assigned for each activity according to intensity (Salonen et
al. 1991). Physical activity was expressed as kcal/d. Current smoking was asked
before blood drawing, and the lifelong exposure to smoking was based on smoking
years. Resting blood pressure was measured in the morning by a trained nurse
with a random-zero mercury sphygmomanometer (Hawksley, Lancing, United
Kingdom). Symptomatic ischaemic heart disease (IHD) or IHD history and
medications were asked by a self-administered questionnaire, and checked by the
interviewer.
4.5 Statistical analyses
Paired samples t-test (P <0.05) was used to statistically assess the differences of
concentrations of retinol, -tocopherol and carotenoids between the compared
HPLC methods (I). A correlation between two HPLC methods was tested both
before and after logarithmic transformation of carotenoid concentration
distribution.
  In the ASTA study (II), differences between baseline and three-month values
with the pooled groups were tested by the paired samples t-test. Means were
compared across the study groups by the independent samples t-test.
  In work III, normal distributions of variables were tested by the Kolmogorov-
Smirnov test, and biased distributions of lipid standardized retinol and -
tocopherol and plasma carotenoids were logarithmically transformed before
association  analyses.  Before  logarithmic  transformation,  one  was  added  to
carotenoid concentration [log(1+x)] to avoid negative values. Associations between
serum LDL conjugated dienes and the other measurements were estimated by
Pearson’s correlation coefficients. Multivariate regression analysis was used to
identify the determinants of serum LDL conjugated dienes. Each of the fat-soluble
vitamins (-tocopherol and retinol) or carotenoids (lycopene, -carotene and -
carotene, lutein, zeaxanthin and -cryptoxanthin) was tested separately in
multivariate-regression analyses together with other possible determinants.
  In the KIHD cancer follow-up study (IV), descriptive data were presented as
mean and standard deviation. Means between cancer cases and the other men were
compared by analysis of variance (ANOVA). RRs and 95% CIs for cancer in tertiles
of the serum concentrations of lycopene were estimated by using the Cox
proportional hazard model. Tests for linear trends were performed by ANOVA.
Correlations between the levels of serum lycopene, other serum antioxidants and
years of smoking were assessed using Pearson's correlation coefficients. Changes in
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the serum/plasma levels of carotenoids over the 20-year period within the Eastern
Finnish population were tested using ANOVA.
5 Results
5.1 MEASUREMENT OF CAROTENOIDS AND METHOD VALIDATION (I)
5.1.1 Optimization of sample preparation
In original work I, it was clearly observed that after single extraction, the addition
of ultrapure water enabled the aqueous layer below the hexane phase to freeze,
thus accelerating phase separation without pipetting. The developed method
appeared to be less tedious and time-consuming than traditional extraction
methods, requiring removal of the organic layer by pipetting. The freezing method
shortened the time spent for sample handling, recovered the hexane layer
completely, and significantly improved the repeatability of the results. The extracts
were also cleaner, because the frozen aqueous layer prevents mixing of the layers
during separation. Table 11 compares the data for intra-assay repeatability, when
organic  layer  was  removed  using  the  traditional  method  and  when  removed  by
decanting after freezing.
Table 11. Repeatability of plasma retinol, -tocopherol and carotenoids by using traditional extraction method
and freezing method. Intra-assay CVs were determined with the pooled Li-heparin plasma of several volunteers.
Pipetting                Decanting
      Intra-assaya                Intra-assayb
                             (N=10)                                     (N=10)
 Compound       Mean ± SD (μmol/l)   CV%    Mean ± SD (μmol/l) CV% P-value
 Retinol              2.30 ± 0.05 2.0         2.47 ± 0.04              1.7
-Tocopherol       27.4 ± 0.36 1.3         31.7 ± 0.33              1.1
 Lutein                 0.27 ± 0.01 2.5         0.26 ± 0.01              2.6
 Zeaxanthin        0.059 ± 0.005 8.8       0.065 ± 0.003            4.0
-Cryptoxanthin   0.33 ± 0.014 4.3         0.27 ±  0.004 1.7
 Lycopene             0.30 ± 0.011 3.8         0.24 ± 0 .003           1.3
-Carotene          0.19 ± 0.006 3.2         0.17 ± 0.003            2.1
-Carotene          0.41 ± 0.01 3.5         0.60 ± 0.01              1.7
Mean 3.7                               Mean 2.0 0.025
aHexane layer (5 ml) was separated by pipetting, bHexane  layer  (2  ml)  was  separated  by  decanting
after freezing at -70ºC, SD = standard deviation, N = Number
5.1.2 Linearity, recovery and precision
Results are from original publication I. The linearities and limits of detection
(LODs) of the method for fat-soluble vitamins (retinol and -tocopherol) and
carotenoids were determined by analysing a series of diluted pure standard
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mixture. The linearities for all compounds were excellent (r >0.999). The LODs
were 0.0100.73 μmol/l exceeding signal-to-noise ratio of 3:1. Concentrations above
the LOD values were regarded as quantifiable, although the variation was higher
than determined for the method with the quality control samples. Spiked plasma
samples at three concentrations with triplicate measurements were analysed to test
the efficiency of the extraction procedure. The absolute and relative recoveries of
all compounds ranged from 80 to 103%. The intra-assay and inter-assay CVs were
determined by analysing the frozen Li-heparin plasma pool and Euro-Trol quality
controls (QCs). The intra-assay CVs of the pooled Li-heparin plasma ranged from
1.1 to 4.0% (normal level) and 3.3 to 9.0% (low level) (N=10). The inter-assay CVs
were obtained by analysing plasma pool during the years 2006-2009 (N=162). CVs
were 5.6–8.7%. The inter-assay CVs of Euro-Trol QCs were obtained by analysis
during the years 2006-2009. The inter-assay CVs were 7.6–20.6% (N=114) and 6.7-
11.2 (N=17) (Level 1). At level 3, CVs were 7.3-11.7 (N=119) and 5.4-10.7 (N=17). The
results for each compound are documented in original publication I.
5.1.3 Stability of extracted sample
Results are decscribed in original publication I. In order to determine how long
storage time affects the concentrations of fat-soluble vitamins and carotenoids, the
extracted plasma pool was stored on the autosampler at +4°C and analysed every
day for one week. We observed that the concentration of retinol increased during
the one-week storage up to 16%, which indicated that the solvent may have
evaporated into the vial and that the retinol molecule was stable during the storage
period. The peak height of the internal standard decreased 7%, indicating that it
had degraded during the one-week period. The increase in the concentration of
retinol was not compensated for by the internal standard. After two days, the mean
concentrations  of  lycopene  and  -carotene  decreased  by  13%  and  11%,
respectively. After a week, these concentrations decreased even further being 29%
and 23% lower than just  after  extraction,  respectively.  However,  lycopene and -
carotene decomposed even more than shown by the percentage values, due to the
opposite effect of solvent evaporation. A slight decreasing trend was seen in the
concentrations of -tocopherol and other carotenoids. These results suggest that
extracted  samples  can  be  stored  for  no  more  than  three  days  at  +4°C  without  a
significant decrease in the concentrations of the carotenoids, except for lycopene
and -carotene, which seemed to be the most sensitive carotenoids for degradation.
5.1.4 Method comparison
For comparing the methods, 10 plasma samples from Kuopio and 24 serum
samples from Madrid were measured using the HPLC methods at the University
of Kuopio (Finland) and the Hospital Universitario Puerta de Hierro (Madrid,
Spain). The correlation coefficients (r) between the two HPLC methods were
acceptable both without (original publication I) and with logarithmic
transformation (Table 12) of the carotenoids and fat-soluble vitamin
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concentrations. For zeaxanthin, no correlation was found between Kuopio and
Madrid. The percentage differences ranged from 0.30% to 26% for the carotenoids,
except for zeaxanthin. The concentrations of retinol, -tocopherol, zeaxanthin, -
cryptoxanthin, lycopene and -carotene differed significantly between the two
HPLC  methods.  However,  the  percentage  difference  for  retinol  (-5.9%)  and  -
carotene (-9.8%) were considered to be acceptable (Table 12). These methods were
also compared with Bland-Altman bias plots, which present the percentage
difference between the two methods. On average, the measurement levels of
retinol, -tocopherol, lutein, zeaxanthin, -cryptoxanthin and lycopene were
higher in Madrid than in Kuopio. For retinol, -tocopherol, lutein, zeaxanthin, -
cryptoxanthin and lycopene the difference between the methods was independent
of the analyte concentration in the sample, whereas for -carotene and -carotene
the difference was higher at the low levels of the carotenoids (broader scattering at
low concentration (Figure 5).
Table 12. Concentrations of retinol, -tocopherol and carotenoids in adult volunteers measured by two HPLC
methods.
         Correlation
                              Kuopio                Madrid           coefficient (r)
 Compound           (μmol/l) (μmol/l) Logaritmic scale   Difference %      P value
 Retinol                1.83 ± 0.58          1.95 ± 0.59           0.9509 -5.9 <0.0001
-Tocopherol       28.8 ± 5.4            24.6 ± 4.8             0.8442 17.1  <0.0001
 Lutein                 0.24 ± 0.10          0.24 ± 0.08        0.8702 -0.3   0.750
 Zeaxanthin        0.050 ± 0.02        0.070 ± 0.04        0.0005 -33.9   0.001
-Cryptoxanthin   0.20 ± 0.14         0.25 ± 0.18 0.9852 -20.4             <0.0001
 Lycopene             0.23 ± 0.07         0.31 ± 0.11 0.8071 -26.2 <0.0001
-Carotene          0.11 ± 0.10         0.12 ± 0.11       0.9536 -9.8   0.012
-Carotene          0.40 ± 0.28         0.40 ± 0.31 0.9836 -0.5   0.517
All values are mean ± SD (N = 34), SD = standard deviation
5.1.5 Concentrations of retinol, -tocopherol and carotenoids in the KIHD study
population within 20-year follow-up
Results are previously unpublished, based on the populations described in
publications III and IV. In both genders, the concentration of lycopene decreased
significantly between follow-up years 420 and 1120 (P<0.0001) (Table 13). Except
for retinol, -tocopherol, -carotene (P<0.0001) and -carotene (P=0.006)
concentrations differed significantly in men between the follow-up years. In
women, the concentrations tended to increase (P<0.0001). Women also had
significantly higher concentrations of -tocopherol and carotenoids than men,
except for lycopene. Lycopene concentrations were at the same level for both
genders.
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Figure 5. Bland-Altman bias plots of the concentrations of carotenoids between two HPLC methods. X-axis = concentration in Kuopio.
Y- axis = difference between two HPLC methods (Madrid-Kuopio) (%).
6 values < -100%
1 value < -100%
6 values < -100 %
1 value < -1 0%
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Table 13. Mean concentrations and standard deviations of serum/plasma retinol, -tocopherol and carotenoids in the
KIHD study population in men and women between follow-up years (4, 11 and 20 y).
Men (n=2569-560)                                     Women (n=615)
                            y 1984-89             4 y          11 y                  20 y           y 1998-2001         7 y
                              (μmol/l)        (μmol/l)      (μmol/l)          (μmol/l)         (μmol/l)         (μmol/l)
     Compound        Mean±SD)     (Mean±SD)  (Mean±SD)      (Mean±SD)     (Mean±SD)     (Mean±SD)
 Retinol            2.11 ± 0.48   2.12 ± 0.43    1.92 ± 0.51      2.11 ± 0.52      1.73 ± 0.45       2.07 ± 0.58
-Tocopherol   20.3 ± 5.8     28.5 ± 7.2     28.7 ± 8.1        32.7 ± 7.6         29.4 ± 7.1        36.3 ± 8.0
 Lycopene                   ND 0.17 ± 0.14    0.22 ± 0.18      0.10 ± 0.08       0.23 ± 0.17     0.11 ± 0.07
-Carotene ND 0.10 ± 0.08          ND 0.12 ± 0.10              ND 0.17 ± 0.13
-Carotene ND 0.40 ± 0.27    0.37 ± 0.25 0.43 ± 0.30 0.55 ± 0.40      0.62 ± 0.40
 Lutein                       ND                ND                 ND         0.24 ± 0.09              ND 0.26 ± 0.11
 Zeaxanthin               ND                ND                 ND           0.038 ± 0.019            ND          0.040 ± 0.017
-Cryptoxanthin        ND                ND                 ND            0.11 ± 0.10               ND 0.16 ± 0.17
ND = not determined, SD = standard deviation
  In both men and women, the concentrations of serum lycopene and -carotene
significantly differed between different seasons (Table 14). The concentration of
serum lycopene was at the lowest in late autumn and early winter. The serum -
carotene concentration was highest in the late summer and autumn, and -carotene
levels were also high in the winter of 2005. During the 20 y follow-up, plasma
lutein and zeaxanthin concentrations were the lowest in the late autumn and early
winter. The concentration of plasma -cryptoxanthin was highest in midwinter and
early spring.
  At  baseline  and  11-year  visits,  the  subjects  kept  a  4-day  food  diary  for
collecting nutrient intake. Correlations between the energy-adjusted dietary intake
and serum concentrations of lycopene were 0.34 for men and women (n=940), 0.33
for women (N=499) and 0.35 for men (N=441), In addition, for -carotene, the
correlations were 0.36 (N=1717), 0.34 (N=900) and 0.38 (N=817), respectively.
5.2 EFFECT OF CAROTENOIDS ON OXIDATIVE MODIFICATION OF LIPIDS (II,
III)
5.2.1 Astaxanthin Supplementation Study (II)
 Healthy young men received 8 mg/d of astaxanthin supplement for 3 months. The
concentrations of plasma 12- and 15-hydroxy fatty acids significantly declined (by
36% and 60%, respectively) in the astaxanthin group (P=0.048 and P=0.047,
respectively) during supplementation, but not in the placebo group.
 No  difference  was  observed  in  the  concentrations  of  12-hydroxy  fatty  acids
between placebo and astaxanthin treated groups at 3 months. The concentration of
plasma 15-hydroxy fatty acid decreased by 22%, though the difference between the
astaxanthin and placebo groups was not significant (P=0.056) No other statistically
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Table 14. Mean concentrations and standard deviations of serum/plasma retinol, -tocopherol and carotenoids
in the KIHD study population in men and women between seasons and follow-up years (4, 11 and 20 y).
Quartile of season
                                    MEN
    1-3a                      4-6b                  7-9c              10-12d P for difference
 (μmol/l)  (μmol/l)  (μmol/l)  (μmol/l)         between
 Compound (Mean±SD)        (Mean±SD) (Mean±SD) (Mean±SD)     seasonse
years 1991-93, 4 y (n=1031)
Retinol 2.12 ± 0.45      2.07 ± 0.47      2.15 ± 0.46      2.10 ± 0.44   0.217
-Tocopherol 29.3 ± 7.6          28.8 ± 7.6      28.9 ± 9.2 27.8 ± 7.5       0.200
 Lycopene             0.15 ± 0.14          0.17 ± 0.14      0.17 ± 0.15  0.12 ± 0.11   <0.0001
-Carotene           0.10 ± 0.07          0.09 ± 0.09  0.10 ± 0.07 0.10 ± 0.08 0.701
-Carotene          0.35 ± 0.26          0.40 ± 0.39       0.43 ± 0.28       0.35 ± 0.21 0.013
years 1998-2001, 11 y (n=851)
 Retinol 1.99 ± 0.59      1.94 ± 0.60       1.90 ± 0.48      1.92 ± 0.62 0.419
-Tocopherol 28.6 ± 8.4         29.0 ± 7.7      28.7 ± 8.6        29.4 ± 8.0 0.777
 Lycopene 0.16 ± 0.15       0.19 ± 0.17       0.23 ± 0.18      0.24 ± 0.20  <0.0001
-Carotene        ND        ND                   ND                    ND
-Carotene 0.31 ± 0.20       0.34 ± 0.26       0.38 ± 0.23      0.44 ± 0.33    <0.0001
years 2005-8, 20 y (n=1228)
 Retinol 2.12 ± 0.46      2.21 ± 0.55      2.20 ± 0.55      2.09 ± 0.54   0.006
-Tocopherol 32.4 ± 7.3          34.6 ± 8.4      32.7 ± 7.8 31.9 ± 7.0      <0.0001
 Lycopene             0.08 ± 0.07          0.09 ± 0.07      0.11 ± 0.08  0.08 ± 0.07    <0.0001
-Carotene          0.13 ± 0.12          0.10 ± 0.07  0.10 ± 0.07 0.14 ± 0.13    <0.0001
-Carotene          0.47 ± 0.38          0.41 ± 0.29       0.44 ± 0.27       0.47 ± 0.33 0.032
 Lutein 0.24 ± 0.08          0.25 ± 0.10       0.25 ± 0.10       0.22 ± 0.08 0.0004
 Zeaxanthin         0.038 ± 0.017       0.039 ± 0.019   0.041 ± 0.021   0.035 ± 0.017 0.0006
-Cryptoxanthin 0.14 ± 0.10          0.12 ± 0.11       0.07 ± 0.07       0.09 ± 0.09    <0.0001
WOMEN
                                                          years 1998-2001,  Baseline (n=913)
 Retinol 1.72 ± 0.50      1.71 ± 0.43      1.81 ± 0.47      1.72 ± 0.44   0.056
-Tocopherol 28.9 ± 6.9          30.6 ± 6.7      30.8 ± 7.1 28.3 ± 7.4       0.0001
 Lycopene             0.17 ± 0.15          0.20 ± 0.16      0.26 ± 0.20  0.22 ± 0.16   <0.0001
-Carotene                  ND                     ND                    ND                    ND
-Carotene          0.51 ± 0.38          0.46 ± 0.34       0.52 ± 0.34       0.59 ± 0.43 0.003
years 2005-8, 7 y (n=620)
 Retinol 2.11 ± 0.63      2.06 ± 0.53       2.13 ± 0.59      2.00 ± 0.56 0.178
-Tocopherol 36.5 ± 8.6         37.7 ± 7.7      35.9 ± 7.4        35.1 ± 8.2 0.025
 Lycopene 0.09 ± 0.06       0.11 ± 0.08       0.13 ± 0.07      0.10 ± 0.07 0.0001
-Carotene 0.19 ± 0.13       0.14 ± 0.12       0.15 ± 0.11      0.20 ± 0.14    <0.0001
-Carotene 0.69 ± 0.47       0.55 ± 0.39       0.60 ± 0.33      0.64 ± 0.37     0.016
 Lutein 0.25 ± 0.10          0.27 ± 0.10       0.29 ± 0.13       0.24 ± 0.09 0.002
 Zeaxanthin         0.042 ± 0.021       0.042 ± 0.017   0.041 ± 0.018   0.036 ± 0.014 0.010
-Cryptoxanthin 0.20 ± 0.18          0.15 ± 0.13       0.11 ± 0.08       0.16 ± 0.22    <0.0001
aQuartile 1-3: January-March, bQuartile 4-6: April-June, cQuartile 7-9: July-September,
dQuartile 10-12: October-December,eANOVA, ND = not determined; SD = standard deviation
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significant differences were found between the study groups in serum lipids,
copper-induced lipid peroxidation, plasma free F2 isoprostanes or serum fatty acid
profiles.
 Astaxanthin was well tolerated during the 3-month supplementation period.
There was no gastrointestinal tract distress or any other side effects. The changes in
liver enzymes did not differ significantly between astaxanthin and placebo groups.
Neither the changes in basic blood profile nor changes in blood pressure were
statistically significant between the study groups.
5.2.2 The Kuopio Ischaemic Heart Disease Risk Factor (KIHD) study (III)
In a statistical preanalysis, we found that gender was an important determinant of
LDL  conjugated  dienes.  Thus,  in  work  III,  men  and  women  were  analysed
separately. Main determinants of serum LDL conjugated dienes in women (N=124)
and men (N=225) are described in Table 15.
 In the linear regression analyses, plasma lycopene concentration (standardized
0.33; P=0.002) was the strongest determinant of serum LDL conjugated dienes
in women. Lycopene explained 7.9% of the variation in conjugated dienes.
 Plasma -carotene (standardized 0.23; P=0.002) appeared to be the most
important determinant of conjugated dienes in men, accounting for 4.8% of the
variation. The regression model with lycopene contributed to 29% of the variation
in serum LDL conjugated dienes for the women, and the model with -carotene to
15% of the variation in serum LDL conjugated dienes for the men. In women, apart
from lycopene, lutein was inversely related with the dienes in explaining 4.1% of
the variation (standardized 0.22; P=0.027).
All regression models showed significant inverse associations between
diastolic blood pressure and conjugated dienes in women, but not in men. The use
of statin medication was associated with increased LDL conjugated diene
concentrations in both sexes. In men, age was associated with conjugated dienes in
all and triglycerides in almost all statistical models independent of the antioxidant
included. Neither lipid-standardized retinol nor -tocopherol was associated with
the conjugated dienes in men or women.
5.3 SERUM LYCOPENE AND THE RISK OF CANCER (IV)
In original work IV, a total of 141 cancers occurred during an average follow-up of
12.6  years,  of  which 55 cases  were prostate  cancers,  17  lung cancers,  16  intestinal
cancers, 10 urinary bladder cancers, and the remaining were of other origin (e.g.,
lymphomas, gastric, oral cavity, liver, renal, cerebral, skin and pancreatic cancers).
 The mean serum lycopene concentration was 0.12  μmol/l  in  the subjects  with
cancer and 0.16 μmol/l in the subjects without cancer during the follow-up. The RR
in  the  highest  tertile  of  the  serum  concentrations  of  lycopene  was  0.63  (95%  CI,
0.40-0.98; P=0.041)  as  compared  to  the  lowest  tertile,  after  adjusting  for  age  and
examination years (Figure 6). After further adjustment for family history of cancer,
waist-to-hip ratio, years of smoking, intake of alcohol, education, physical activity
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  Table 15. Main determinants of serum LDL conjugated dienes in women (N=124) and men (N=225).
                            Lipid standardized -tocopherol        Lipid standardized retinol
-Tocopherol                                     Retinol
                                       Women    Men         Women        Men
    P  P *           P         P
Log antioxidant -0.103 0.282  -0.132  0.070 0.053 0.597  -0.026 0.716
Age -0.015 0.878  0.174  0.017      -0.006 0.948  0.177 0.016
BMI                          0.118     0.260   0.070  0.344       0.121     0.255    0.076    0.310
DBP                        -0.251     0.014   0.009  0.902      -0.248     0.016    0.013    0.855
Statin medication  0.225 0.026  0.151  0.062 0.200 0.049  0.143 0.078
TG  0.015 0.883  0.176  0.020 0.019 0.852  0.145 0.053
Lycopene -Carotene
                                       Women Men        Women Men
 P  P * P  P
Log antioxidant           -0.328 0.002  -0.047  0.528      -0.213 0.050  -0.109 0.132
Age                            -0.120 0.237  0.171  0.021      -0.051 0.614  0.178 0.014
BMI                             0.098  0.323   0.073  0.330       0.062     0.568    0.053    0.482
DBP                           -0.222  0.023   0.023  0.750      -0272      0.007    0.017    0.810
Statin medication    0.176 0.065  0.144  0.076 0.180 0.070  0.136 0.092
TG                            -0.039 0.687   0.147  0.049      -0.018 0.855  0.141 0.058
-Carotene                                  Lutein
                                       Women Men         Women Men
 P  P * P  P
Log antioxidant           -0.208 0.073  -0.233  0.002      -0.224 0.027  -0.023 0.748
Age                           -0.017 0.859  0.185  0.009      -0.030 0.758  0.178 0.015
BMI                            0.076   0.475   0.016  0.830       0.068     0.521    0.072    0.340
DBP                           -0246   0.014   0.016   0.830     -0.259     0.009    0.072    0.340
Statin medication    0.193 0.051  0.149  0.059 0.202 0.038  0.078 0.281
TG                            -0.056 0.604  0.131  0.073 0.002 0.984  0.149 0.047
Zeaxanthin                      -Cryptoxanthin
                                      Women Men       Women              Men
 P  P * P  P
Log antioxidant           -0.151 0.127  -0.095  0.185      -0.053 0.598  -0.123 0.088
Age                           -0.017 0.864  0.177  0.015      -0.013 0.898  0.182 0.012
BMI                            0.119   0.252   0.068  0.367       0.128      0.224   0.081    0.276
DBP                          -0265    0.009   0.012  0.869      -0.260      0.011   0.016    0.819
Statin medication    0.199 0.044  0.140  0.083 0.207 0.039  0.168 0.041
TG    0.001 0.989  0.160  0.033 0.015 0.881  0.160 0.032
Antioxidant = lipid standardized -tocopherol or retinol, lycopene, -carotene, -carotene,
lutein, zeaxanthin or -cryptoxanthin, in turn.  = standardized regression coefficient,
Statin medication, 0 = no, 1 = yes, BMI = Body mass index, DBP = Diastolic blood pressure
TG = triglycerides. Blood leucocyte count was included in all the models
and serum folate, men in the highest tertile of the serum concentrations of lycopene
had a 45% lower risk of cancer than those in the lowest serum lycopene tertile
(RR=0.55; 95% CI, 0.34-0.89; P=0.015). With serum lycopene treated as a continuous
variable, the adjusted RR was 0.18 (95% CI, 0.038-0.86; P=0.031). Serum retinol, -
tocopherol, -carotene and -carotene were not related to a risk of cancer when
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examined as continuous variable. No association was observed between lycopene
and prostate cancer risk in our cohort. For other cancers, after adjustment for
covariates, men in the highest tertile of serum concentrations of lycopene had a
57% lower risk of other cancers compared with the lowest serum lycopene tertile.
Figure 6. Relative risks (RR) and 95% confidence intervals (CI) of cancers by tertiles of serum levels of lycopene
by using Cox proportional hazard’s model after adjustment for age and examination year (model 1); model 1 +
family history of cancer, waist-to-hip ratio, years of smoking, intake of alcohol, education, physical activity and
serum folate (model 2).
* P <0.05.
6 Discussion
6.1 METHODOLOGY
Liquid-liquid extraction with hexane is the most often used method for purification
of carotenoids from biological fluids, since carotenoids are usually soluble in non-
polar solvents (Su et al. 2002). At a preliminary stage in the present work, the
sample preparation process included precipitation of proteins with 1 ml of ethanol
containing internal standards and thereafter single extraction with 5 ml of hexane
(Porkkala-Sarataho et al. 1996). Hexane layer separation turned out to be laborious
and time-consuming, since separation was carried out by pipetting. A more
convenient,  faster  sample  preparation  would  provide  for  a  larger  number  of
samples to be prepared in a working day, a highly desirable feature in large
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studies. A critical step in the liquid-liquid extraction is the phase separation. We
clearly observed that after single extraction, the addition of ultrapure water
enabled the aqueous layer below the hexane phase to freeze. The present method
offers five advantages: 1) freezing of the aqueous layer speeds up the phase
separation  step;  2)  the  developed  method  appears  to  be  less  tedious  than
traditional extraction methods, which require removal of organic layer by
pipetting; 3) the freezing method shortens the time spent in sample handling; 4)
our method allows a more complete recovery of the hexane layer and 5) this
method improves the repeatability of the results.
  The linearity of all analytes was excellent and can be applied using only one
standard level. We used the plasma pool as a secondary calibrator, since retinol, -
tocopherol and carotenoids have been reported to be stable in frozen serum from
five months up to 4 years, depending on the temperature (Talwar et al. 1998;
Comstock  et  al.  1995;  Craft  et  al.  1988).  In  organic  solvents,  carotenoids  become
unstable (Su et al. 1999), thus increasing the variablility of the method. The inter-
assay coefficient of variation was below 10% for all analytes using freezing,
indicating excellent repeatability of the method. Absolute recoveries of carotenoids
were at the same level as reported in previous studies (Lee et al. 2003; Talwar et al.
1998; Gueguen et al. 2002).
  We  connected  two  Synergy  Hydro–RP80A  columns  in  series  in  order  to
improve separation of lutein and zeaxanthin. Initially, we used one column, but
zeaxanthin co-eluted with lutein, similar to other HPLC methods (Talwar et al.
1998; Gueguen et al. 2002; Nierenberg & Nann 1992). However, another type of
column (e.g., C30) would have further improved the selectivity (Rajendran et al.
2005). Lyan et al. also connected two columns in series, thereby increasing the
selectivity and enabling successful separation of zeaxanthin from lutein, and
canthaxanthin cis-isomers from trans-lycopene (Lyan et al. 2001).
  We  compared  our  HPLC  method  with  the  HPLC  method  at  the  Hospital
Universitario Puerta de Hierro (Madrid, Spain) to confirm the reliability of the
validated method. Correlation between the methods was adequate, except for
zeaxanthin. The low correlation of zeaxanthin between methods may be due to
partial coelution of zeaxanthin with lutein, even though calibration using peak
height decreases any possible interference (work I, figure 2). Unfortunately, in our
HPLC  system,  it  was  not  possible  to  use  the  detector  to  verify  the  purity  of  the
peaks with spectrophotometric wavelength scanning.
6.2 CONCENTRATIONS OF RETINOL, -TOCOPHEROL AND CAROTENOIDS IN
THE KIHD STUDY POPULATION AT 20-YEAR FOLLOW-UP
In this Eastern Finnish middle-aged KIHD study population, serum/plasma
concentrations of carotenoids and -tocopherol tended to increase, except for
lycopene, over the 20-year follow-up period. Changes in plasma levels may be a
consequence of dietary changes. From the late 1980s to the beginning of the 2000s,
-tocopherol values nearly doubled. For -carotene and lycopene, we have the first
values from the mid-1990s and the last values until the beginning of 2005, during
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which plasma -carotene had increased by 8%, while lycopene had decreased by
40%. It is possible that consumption of tomatoes or tomato products had decreased
as the population grew older. Furthermore, the correlation between dietary intake
and blood concentrations of lycopene has been reported to be poor (r = 0.190.47)
(Scott et al. 1996; El-Sohemy et al. 2002). At the baseline and 11-year reexamination
visit, dietary intake data was collected using a 4-day food diary and analysed for
nutrients (Rissanen et al. 2003). We found that 4 days is too short a time to estimate
the intake of carotenoids, since there was large day-to-day variation in the intake of
the carotenoids, such as lycopene (Rissanen 2003). The plasma concentration of
lycopene was lowest in 20 y (men) or 7 y (women) follow-up visit (the mean age
for men and women was ~70 years). Seasonal variations in the concentrations of
carotenoids were also observed. Lycopene concentrations tended to be highest
between July and September, when tomato consumption is usually most abundant.
Conversely, consumption of carrots seems to be highest in the late autumn and
winter, reflecting the highest concentrations of -carotene and -carotene in the
blood.
 We cannot exclude the possibility that the decrease in lycopene levels from 11 y
to 20 y (men) and from baseline to 7 y (women) is partly due to analytical changes.
During the 20-year follow-up visit, the sample type was Li-heparin plasma,
whereas the 4-year and 11-year visits collected samples from serum. It has been
reported that no significant differences in the concentrations of carotenoids can be
found between samples measured from serum or Li-heparin plasma, although
these concentrations were slightly higher in serum (Olmedilla-Alonso et al. 2005).
Another HPLC method was used in the 20-year follow-up for carotenoid analysis
than had been used in previous follow-up visits. Peak-height was used in our
previous and current method for quantification of carotenoids. We observed that
total lycopene (cis+trans) was not measured in our previous follow-up visits.
Therefore, difference in the levels of lycopene between methods was not significant
under in vivo circumstances.
6.3 ROLE OF CAROTENOIDS IN LIPID OXIDATION
6.3.1 Effect of astaxanthin supplementation on lipid oxidation
In  original  work  II,  we  found  that  astaxanthin  supplementation  of  8  mg/d  may
prevent lipid oxidation by decreasing the levels of plasma 12- and 15-hydroxy fatty
acid, which are formed by oxidation of polyunsaturated linolenic and linolic acids.
This decrease was almost significantly comparable to the placebo group. Fatty
acids may be most sensitive to oxidation. C18 hydroxy fatty acids are good
indicators during the first step in the oxidation of LDL lipids (Wang et al. 1992). In
a study by Iwamoto and co-workers, 24 young healthy volunteers consumed 1.8-
21.6  mg  of  astaxanthin/d  for  2  weeks.  The  LDL  lag  time  increased  dose-
dependently between days 0 and 14. The authors found no difference in the
oxidation of LDL in the control group (Iwamoto  et  al.  2000).  In  a  recent  study,
astaxanthin supplementation (2-8 mg for 4 week) decreased oxidative stress by
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decreasing a DNA damage biomarker 8-hydroxy-2´-deoxyguanosine, but did not
affect lipid oxidation (Park et al. 2010).
  In a previous study, in which astaxanthin doses were greater than 8 mg/d, LDL
lag time increased significantly (Iwamoto et al. 2000), suggesting that the daily
dose  of  astaxanthin  must  be  higher  than  8  mg  to  achieve  any  impact  on  the  lag
time. However, astaxanthin supplementation did not have any effect on another in
vivo lipid oxidation marker (free F2 isoprostane concentration). Astaxanthin had no
more effect on ex vivo lipid oxidation markers than did the placebo. The reasons
why astaxanthin has no effect on other markers of lipid oxidation may include the
young age of the subjects, who were healthy, non-smokers and had not been
exposed to increased oxidative stress, or that the 8-mg supplement simply can not
decrease lipid oxidation as measured by these markers.
  Astaxanthin supplements were effectively absorbed from capsules into the
systemic blood circulation and were found to be a safe dietary supplement, as it
did not cause any gastrointestinal tract distress or other side effects. In previous
supplementation studies, no side-effects, apart from headache, were observed,
although astaxanthin doses were much higher than in our work (Osterlie et al.
2000; Coral-Hinostroza et al. 2004; Mercke Odeberg et al. 2003). Spiller et al.
extensively studied the safety of astaxantin using a smaller daily dose (6 mg) than
in our work and found no significant side-effects (Spiller & Dewell 2003).
6.3.2 Carotenoids and oxidative modification of LDL
Plasma lycopene, lutein and -carotene were the most powerful antioxidants for
explaining the content of in vivo oxidatively modified LDL in blood circulation
(original work III).
  Lycopene  was  the  strongest  determinant  of  serum  LDL  conjugated  dienes  in
women, even though plasma lycopene concentration or its standard deviations did
not differ between sexes. Moreover, lutein was an important antioxidant in women
that  decreased  the  concentrations  of  LDL  conjugated  dienes.  In  particular,  -
carotene was the most efficient antioxidant in men. The low plasma concentration
of  -carotene  and  other  antioxidative  vitamins  in  men  may  enhance  men’s
endogenous antioxidative capacity, resulting in a lower oxidative status in vivo
and lower conjugated diene content in LDL.
  A natural carotenoid mixture increased the lag phase in Cu2+ induced oxidation
of LDL. The beneficial effect may probably be a consequence of interaction
between carotenoids (Kioskias & Gordon 2003). Lin and colleagues (Lin et al. 1998)
have reported a decreased oxidation of LDL in healthy female non-smokers, who
consumed a supplement rich in -carotene and minor amounts of -carotene,
lycopene, zeaxanthin and lutein. This finding is in agreement with the notion that
although a single antioxidant may have little influence on health, a combination of
different antioxidants, as found in fruits and vegetables, may improve the effect.
The combination of phenolic compounds and carotenoids has been shown to have
synergistic effects by preventing human LDL oxidation more effectively than
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carotenoids alone (Milde et al. 2007). Thus, co-operation between antioxidants may
have affected the results of our study (III).
  We were interested in the suitability of measuring LDL conjugated dienes as a
marker of in vivo lipid oxidation. We wanted to examine what aspect could affect
their formation. It was shown that all powerful antioxidants, such as -tocopherol,
observed in in vitro methods were not significant under in vivo circumstances.
6.4 ROLE OF LYCOPENE IN CANCER
In original work IV, we found that serum lycopene decreased the risk of cancer.
The association between lycopene and prostate cancer risk has received the most
attention (Rao & Rao 2007). Prostate cancer is the most commonly diagnosed
malignancy in males (Cheung et al. 2008) and almost 40% of the cancers were
prostate cancers in our cohort. The analysis was stratified to prostate cancer and
other cancers to study whether the inverse relationship with serum lycopene
would be similar for both groups. The association was observed for other cancers,
but not for prostate cancer.
  The mean blood concentration of lycopene has widely varied between different
populations in Europe and USA (Table 2). The low blood level of lycopene is a
consequence of a low dietary intake of tomatoes or tomato products or due to
malabsorption or maldigestion (Drai et al. 2009), or possibly a result of increased
oxidative stress in the body. Since our study population had very low
concentrations of lycopene, but the concentration range was quite wide (0-1.02
μmol/l), statistical analysis showed that the protective effect against cancer was
stronger than the results of site-specific cancers from other countries.
 This is the first study to show a significant association between decreased
serum lycopene levels and the risk of any cancer. Our results show that in Eastern
Finnish men, a serum lycopene concentration >0.19 μmol/l may be a threshold
value for decreasing the risk of cancer.
 Two previous studies (Table 7) have reported a significant association between
a low plasma concentration of lycopene and increased prostate cancer risk. These
studies found that the protective plasma concentration of lycopene was >0.28
μmol/l (Lu et al. 2001) and >0.96 μmol/l (Zhang et al. 2007). Interestingly, the cutoff
of the lowest plasma lycopene quartile (<0.18 μmol/l) (Lu et al. 2001) is nearly the
same as the highest tertile (>0.19 μmol/l) in our Eastern Finnish population of men.
Our results and those from previous studies suggest that a plasma lycopene
concentration higher than about 0.2 μmol/l might present a threshold value for
decreasing the risk of cancers, though this requires further research. In addition,
the protective concentration of lycopene may depend on the type of the cancer.
 Serum lycopene concentrations may provide an indicator for other beneficial
dietary or lifestyle factors. In addition to lycopene, tomatoes contain numerous
other phytochemicals, including carotenoids and polyphenols. Many of these
nutrients and phytochemicals possess antioxidant and anticancer properties
(Stacewicz-Sapuntzakis & Bowen 2005), and an interaction with lycopene may
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contribute to the inverse associations found in our study. However, it would
appear that the protective effect of lycopene on cancers seen in this study is not an
over-estimate due to confounding of retinol, -tocopherol, -carotene and -
carotene,  as  they  were  not  associated  with  the  risk  of  cancer  and  their
concentrations did not differ between the study groups. In addition, the correlation
between blood lycopene concentrations and total intake of total vegetables and
fruits has been shown to be very low (Campbell et al. 1994). Thus, blood lycopene
may not simply be a reflection of a healthy diet (Rissanen 2003).
6.5 Strengths and limitations of the studies
The strengths of original work I include accurate validation of the HPLC method,
method  comparison,  measurement  of  carotenoids  that  have  not  been  analysed
before  in  our  laboratory.  However,  one  limitation  of  this  study  is  the  poor
correlation of zeaxanthin between the compared HPLC methods. Zeaxanthin peak
purities  could  not  be  checked  in  our  apparatus,  and  the  resolution  of  lutein  and
zeaxanthin could be improved.
 The strengths of original work II are its randomized double-blind design, use
of numerous in vivo and in vitro lipid oxidation markers and the profound testing
of astaxanthin supplement safety. If a larger effect of astaxanthin on lipid oxidation
were desired, the astaxanthin dose would need to be higher than 8 mg to achieve
any impact on most lipid oxidation markers. However, the 8 mg of astaxanthin per
day corresponds to over 1.5 kg of farmed rainbow trout. Unfortunately, serum
LDL conjugated dienes were not measured in the astaxanthin supplementation
study.
 In work III, the main determinants of serum LDL conjugated dienes were
assessed  and  the  carotenoids  proved  to  be  the  most  powerful  determinants.  The
large range of possible determinants, including biochemical, anthropometric,
behavioural and health measurements, were available to achieve reliable models
for statistical testing. The lack of nutrient intake data is a limitation of this study.
However, at the baseline and at the later follow-up visit of the KIHD, dietary
intake data were collected using a 4-day food diary and concentrations of
nutrients. We found 4 days to be too short a period of time to estimate the intake of
some  carotenoids,  since  there  was  a  large  day-to-day  variation  in  the  intake  of
carotenoids, such as lycopene. The human body may increase the endogenous
antioxidative status in response to increased oxidative stress due to a low intake of
dietary antioxidants or other unbalanced condition. Unfortunately, we did not
have the possibility to measure endogenous plasma urate or glutathione or any
other endogenous antioxidative enzymes, such as glutathione peroxidase,
glutathione transferase and paraoxonase, or to evaluate their effect on serum LDL
conjugated dienes.
 The strengths of study IV include its prospective population-based design,
complete follow-up (no losses), and reliable assessments of incident cancers. The
limitations of this study might be that we included the variables of smoking at the
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baseline in the model, even though we cannot exclude any possible residual
confounding factors due to smoking, such as those related to a change in smoking
habits after the baseline. The small numbers of cancer cases reduced the possibility
of studying site-specific cancer risk, and the sum category of all non-prostate
cancers may include cancer types with varying associations with lycopene.
7 Conclusions
The aim of the present study was to develop a rapid and simple method for
analyzing carotenoids and evaluating their role in lipid oxidation and cancer. It
was shown that plasma astaxanthin, lycopene, lutein and -carotene may decrease
oxidative modification of LDL (serum LDL conjugated dienes, C12 and C15 hydroxy
fatty acids). Furthermore, serum lycopene may decrease the risk of cancer.
The main conclusions are:
1. The validated HPLC method for analysis of retinol, -tocopherol and
carotenoids (lutein, zeaxanthin, -cryptoxanthin, lycopene, -carotene and
-carotene) is simple, quick and repeatable for routine measurement of
retinol, -tocopherol and carotenoids.
2. Concentrations of -tocopherol and carotenoids, except for lycopene,
tended to increase in men and women, with increasing age, which may be
explained  by  the  increased  consumption  of  fruits  and  vegetables  that  has
occurred between the late 1980s and the beginning of the 2000s. However, it
may be that elderly people consume less tomatoes and tomato products
than do younger people, as indicated by the lower lycopene concentration
found during the follow-up years in both sexes.
3. Astaxanthin supplemented as capsules was efficiently absorbed from the
intestine into blood circulation, and was well tolerated. Nearly significant
decrease was observed in the in vivo oxidation of fatty acids in healthy
men.
4. Lycopene, lutein and -carotene were the most powerful determinants for
explaining the content of in vivo oxidatively modified LDL in serum.
5. In the population of Eastern Finnish men, high concentrations of serum
lycopene were associated with a decreased risk of cancer. However,
lycopene was not associated with prostate cancer in this population.
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Carotenoids are colourful compounds, 
present in fruits and vegetables, syn-
thesised by plants and micro-organ-
isms. Carotenoids act as antioxidants 
and possibly decrease in vivo lipid 
oxidation. Lipid oxidation is known to 
be a risk factor for development of ath-
erosclerosis. Carotenoids are thought 
to be responsible for the beneficial 
properties of fruits and vegetables in 
preventing human diseases, including 
cardiovascular diseases and cancer. 
In this study, we observed that serum/
plasma carotenoids may decrease li-
pidoxidation in vivo. In addition, high 
serum concentrations of lycopene may 
decrease the risk of cancer in middle-
aged Finnish men.
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